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ABSTRACT
Advances in neonatal care during the past 15 years have resulted in an increased 
sui*vival rate for preterm newborn infants with birth weight o f less than 1500 grams. 
Despite therapeutic improvements, infection remains a major problem in this group of 
babies due to their increased susceptibility to infection.
In a double blind, placebo controlled trial, we investigated the effect of 
intravenous immunoglobulin (IgG) in the prevention of nosocomial infection in very 
low birth weight infants (with birth weight < 1500 grams and gestational age < 3 2  
weeks).
Patients were recruited from the Neonatal Intensive Care Unit at the Glasgow 
Royal Maternity Hospital. Thirty eight infants were enrolled into the trial and all 
needed intensive life support and/or parenteral nutrition through a long line.
After randomisation 19 were given IVIG and 19 were used as controls. Four 
babies died early in the study and were excluded.
The babies were intensively monitored during the study period for the number 
o f proven or suspected episodes o f infection and any complication of therapy. 
Additional information about their ability to resist infection was obtained by checking 
their opsonic activity.
Babies < 1000 grams birth weight were given 700 mg/kg o f IVIG. Babies with 
1001 “ 1500 grams were given 500 mg/kg o f IVIG. The placebo given to control 
group was 5 % dextrose. These doses were repeated at two weekly inteiwals so long 
as the babies needed intensive care.
Ill
We conclude that the administration of IVIG did not provide effective 
prophylaxis for late-onset sepsis. IVIG appears to be well tolerated by very low birth 
weight infants. No significant side effects were observed.
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LBW Low birth weight
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CFU-GM Colony forming unit- granulocyte macrophage
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Chapter 1
1.1 Introduction and Aim of the study
Advances in neonatal care during the past 15 years resulted in an increased 
survival rate for preterm new-born infants, particularly those weighing less than 1500 
grams at birth^^’^ l As a result, a considerable number o f very low birth weight infants 
stay for up to several months in neonatal intensive care units, exposed to various 
invasive procedures and they are susceptible to serious nosocomial infections. The 
majority o f nosocomial infections in these neonatal units occur in preterm infants with 
an attack rate o f up to 20%l^l During the hospital stay which may range from a few 
weeks to several months, many preterm infants will experience more than one episode 
o f nosocomial infection. Increased susceptibility to nosocomial infections in preterm 
infants is multifactorial. Conditions associated with risk include disruption o f mucosal 
and skin barriers during invasive procedures such as intubation, umbilical arterial and 
venous catherisation, exposure to nosocomial pathogens, multiple courses o f broad- 
spectrum antibiotics, and immaturity o f host defence mechanisms.
Immaturity o f host defence mechanisms result in a reduced humoral immunity. 
B lymphocytes do not mature to become plasma cells and produce IgG. This together 
with the fact that preterm infants are born with low serum IgG concentrations 
contributes to veiy low levels of circulating IgG During the first weeks o f life the 
deficiency o f transplacentally acquired specific antibody causes an increased risk to 
the infants o f certain neonatal infections, such as those caused by group B (3- 
haemolytic streptococci and Escherichia coli capsular serotype
Other factors affecting humoral immunity include complement and fibronectin. 
These are necessary for opsonization o f bacteria and are present in considerably 
reduced concentrations in infants born prematurely. Cellular immunity is also 
defective in preterm infants. Quantitative and qualitative deficiency in the myeloid and 
phagocyte cells lead to inability o f these cells to respond to specific bacterial antigens 
so that the infants ability to respond to  bacterial infections is further compromised.
During the last decade there have been a number o f attempts to enhance the 
neonatal host defence mechanisms by using granulocyte transfusions to provide 
improved cellular immunity and opsonization. Exchange transflision with fresh donor 
blood, fibronectin transfusion to foster neutrophil adhesion and opsonization, and the 
use o f intravenous immunoglobulin are therapeutic strategies which have been used in 
an attempt to improve opsonization and bacterial killing.
M ost neonatal infections are bacterial in origin and most reported studies have 
focused on the use o f intravenous immunoglobulin (IVIG) in an attempt to prevent or 
to reduce the severity o f neonatal infections.
Some studies have shown a beneficial effect o f IVIG in prophylaxis and in 
therapy whilst others have failed to demonstrate any benefit. A variety o f outcome 
measures such as the incidence o f culture proven sepsis, a reduced mortality and a 
reduction in the duration o f stay in hospital were used in these intervention studies but 
there remains considerable uncertainly about the effectiveness of IVIG.
significantly reduce neonatal sepsis there would be a major health benefit to be gained.
In developing countries neonatal bacterial infections are a major cause o f death 
and severe handicap in those who suivive. I f  IVIG were to be shown to prevent or
■ ■ : :
The present study has been set up in order to explore fijrther the value of IVIG in the 
prevention o f bacterial infections in very low birth weight infants.
1.2 Neonatal Infection
Neonatal infection is an important cause o f morbidity and mortality in new-born 
infants especially those born prematurely. Neonatal bacterial sepsis occurs in 
approximately 1 to 10 per 1000 live births and is increased almost fourfold in preterm 
babies^' '^^l Advances in intensive care over the last two decades have resulted in 
improved survival o f babies born before 32 weeks gestation and/or weighing under 
1500 grams. Because these babies stay in a hospital for several weeks prior to 
dismissal there is a 15-30%^^^ risk o f late onset nosocomial infection.
This is the result o f multiple risk factors which including immaturity of host 
defence mechanisms, endotracheal intubation, arterial or venous umbilical 
catheterization, the insertion o f long lines which result in disruption o f mucosal and 
skin barriers and multiple courses o f antibiotic. The incidence o f infection in these 
infants is about 24-32%^^’^ ^^  Despite the development o f new broad spectrum 
antibiotics, the mortality rate has remained unacceptably high and ranges from 11 to 
33% and as high as 20% to 75%^^’^ ^^  in these babies who are neutropenic.
The incidence o f neonatal sepsis varies among hospitals due to  the differences in 
patient population with respect to risk factors. Two studies^^’^ ^^  reported that the 
incidence o f neonatal sepsis were under estimated. They reported that bacteria were 
isolated from the blood o f more than 40 % of babies who died during the first twenty 
eight days o f life and that in two tliirds of the 40%, post-mortem cultures provide the 
only evidence o f infection.
infection. These can be grouped into two groups: maternal and neonatal.
A. Maternal risk factors
1. Prolonged rupture of membranes and chorioamnionitis
Many studies^ have shown that the incidence o f documented sepsis in the 
neonate born to mothers with rupture of membranes for more than 24 hours is 
approximately 1%. With signs and symptoms of chorioamnionitis the risk o f sepsis 
increases to 3-5%.
The morbidity and mortality associated with neonatal sepsis is inversely related 
to gestational age, VLBW infants exhibiting a higher mortality than full term infants. 
They are also pathogen specific, with sepsis due to group B streptococci resulting in a 
higher mortality than sepsis due to staphylococci. The outcome o f neonatal sepsis is 
also dependent on the immunological and physiological status o f the baby at the time 
o f presentation, the presence o f perinatal risk factors, the use o f invasive supportive 
life measures, early diagnosis and treatment with appropriate antibiotic therapy and 
the management o f metabolic and respiratory acidosis^^'^^l Further, sepsis associated 
with hypotension, disseminated intravascular coagulation and other organ dysfunction 
is associated with a mortality that approaches 90% in the VLBW infants
1.3 Predisposing Factors of neonatal Infection
There are multiple risk factors which predispose premature infants to neonatal
' - 'i i i
-I:
Boyer et studied the correlation between the duration o f mpture o f the 
membranes and clinical neonatal infection with GBS and noted the attack rate ranged 
from 0.8 per 1000 live births when the membrane has mptured for less than 6 hours, 
up to 10.8 per 1000 live births if the membranes were mptured for more than 24
hours. Over all, the relative risk o f developing early onset disease was 7.2 times 
higher when the membranes were mptured for more than 18 hours before birth. 
Intrapartum fever >37.5 increases the sepsis rate to 6.5 per 1000 live births 
compared with 1.5 per 1000 live births in women who were afebrile. The placental 
pathogenic diagnosis is easy to make, but that result is rarely known in time to 
influence clinical management.
2. Maternal colonisation
Maternal colonisation with GBS without other clinical complications carries a 
risk o f neonatal sepsis o f 0.5% to 1%^ ^^ -^ Materno-fetal transmission can occur from 
an ascending route in utero or during birth through a colonised birth canal. The 
vertical transmission rate ranged from 42% to 72% among infants delivered by 
colonised womei7^^l Sepsis rates for clinical disease are low in colonised neonates 
and range from 0.7 to 3.7 per 1000 live births during the first week o f life, and 0.5 to 
1.7 per 1000 live births after 7 days o f life.
Another study^^^  ^ found the sepsis rate during the perinatal period in infants born 
to GBS colonised mothers was 1% to 2% but increased to 15.2% with premature 
onset o f labour of <37 weeks, to 10.7% with chorioamnionitis or PROM of >24 hours 
and to 9.7% with maternal post partum bacteraemia^^^l
Twin gestation may be at increased risk for GBS sepsis when associated with 
p r e m a t u r i t y ^ O n e  explanation may be that GBS infection o f a previous sibling 
may be a risk factor^^^b Presumably the mothers o f these babies do not have sufficient 
GBS antibody to pass to their fetus or deliver a preterm baby that has not been in 
utero long enough to receive protective antibody. A major limitation to the ability to 
manage GBS infection postnatally is that the majority o f early onset disease is 
acquired in utero.
3. Maternai urinaiy tract infection
Unless treated and resolved before labour, urinary tract infection is associated 
with an increased risk of infection in the neonate because o f an increased risk of 
preterm deliveiy and chorioamnionitis^^^I
B. Neonatal risk factors
1. Prematurity and low birth weight
The preterm baby is deficient in most arms o f the immune system including 
immunoglobulin, complement, fibronectin, opsonic function and phagocytic capacity 
o f Colonisation rates with GBS are similar between preterm and term infants
but the rate o f GBS infection is considerably higher in preterm infants. Following 
PROM the rate o f infection in the preterm infant is 8 to 10 times higher than in the 
term infant, these infants exhibiting a sepsis rate ranging from 4% to 
Boyer et alJ^^  ^prospectively studied 61 infants with GBS infection. They noted a high 
sepsis rate among infants weighing less than 2500 gram, 7,6 per 1000 live births in 
comparison to 1.1 per 1000 live births in term infants. In another study^ "^^  ^ the rate of 
sepsis was 8 times greater in infants weighing 1000 - 1500 gram compared with those 
weight 2000 - 2500 gram. Meningitis occurred 3 - 1 7  times more often in those 
weighing less than 2500 gram compared with those weighing more than 2500 gram.
2. Perinatal asphyxia
In a study by Geme et al.^ "^^  ^ a 5 minute Apgar score o f <6 in the presence of 
PROM was a useflil predictor o f neonatal sepsis as choriamnionitis. A Danish study^^^  ^
found that 27% of preterm infants with PROM and perinatal asphyxia had proven 
sepsis.
3. Male gender
Observation for many years confirms that male infants are 2-6 times more likely 
to develop perinatal sepsis than female infants^ '^^’^ ^l The reasons for this finding have 
not been elucidated.
4. Traumatic deliveiy
Forceps and vacuum delivery carry a great risk o f trauma, skin aberration and 
birth asphyxia.
1.4 Microbiology
1. Group B beta haemolytic streptococci [GBS]
This is the most common cause o f neonatal sepsis and meningitis in the United 
States with an incidence o f 2-4 per 1000 live births. It most commonly occurs during 
the first few days o f life (early onset disease) with a mean onset o f 20 hours^^^l It is 
acquired from infected amniotic fluid or swallowed inoculum during transit through 
the vaginal canal. The carriage rate at deliveiy for mothers was 20% and for new-born 
12%. The rate o f early onset disease is liigher in infants found to be heavily colonised 
at birth. Preterm delivery, prolonged labour, premature lupture o f membranes and 
maternal infection enhance the risk o f early disease. Late onset disease occurs after 
the first week of life with a mean onset o f 24 days. The organisms may be acquired 
from the mother or nosocomially. It has an incidence o f 1-2 per 1000 live births. 
Mortality rate from GBS infection varies from 20% to 50% and is more common in 
preterm infants.
The type III strain o f capsular serotype of GBS is the main organism causing 
disease in the neonate. GBS has a type specific polysaccharide which protects it from 
phagocytosis, unless the organism is opsonised (which involves the deposition of
''AM
prognostic sign with a mortality rate of 50% - 75%.
specific antibody and/or complement on the bacterial surface). Neutropoenia is 
common in GBS disease occurring in up to 30% of affected neonates. It is a poor
2, Escherichia coli K1
The overall incidence o f E-coli infection is estimated to be 1-2 per 1000 live 
births. The majority of these infections are caused by strains possessing the K1 
polysaccharide capsuW^^l The intestine o f new-born infants, which is sterile in utero.
becomes colonised by E-coli shortly after birth. The colonising strains originate from
*the maternal faecal flora or are acquired from the environment.
3. Listeria monocytogenes
It is difficult to know the true incidence o f Listeria infection. One study in the
United States between 1980-1983 suggests that the incidence o f neonatal infection 
may be as high as 0.6 per 1000 live births^^^  ^ with a mortality rate o f 19.1%. 7;
4. Haemophilus influenzae [HI]
Infection with HI occurs usually in utero or in the immediate post-partum 
period. It is associated with prematurity in 83%. The overall mortality rate is 55% and 
may be as high as 90% in preterm neonates o f  less than 30 weeks gestation^^^l
5. Nosocomial infection
Coagulase negative staphylococci have become an important cause of
nosocomial bacteraemia in recent years. This may be due to a change in the nursery 
population with an increased proportion o f very low birth infants. It accounts for 
more than 50% of bacteraemia in neonatal intensive care units. Neonatal sepsis and 
meningitis with coagulase negative septicaemia are associated with significant 
morbidity and a mortality rate as high as 10%^^  ^I
___
Coagulase negative staphylococci are the most common infective agent causing 
septicaemia after 48 hours o f age. Nosocomial infection is a significant problem for 
neonates requiring prolonged care in the nursery especially in the case o f very low 
birth infants. The overall incidence has been reported to be as high as 15% to 30% in 
babies whose birth weight was less than 1500 grams^^^l Beyond the first week o f life, 
the neonate who remains in special care is likely to be colonised with endogenous and 
nosocomially acquired flora especially coagulase negative staphylococci, 
Staphylococcus aureus and other organisms causing late onset disease such as GBS 
and Listeria. The strains of coagulase negative staphylococci most frequently 
associated with neonatal infection are often resistant to a wide range o f antibiotics and 
are usually spread from patient to patient on the hands o f nursing and medical staff.
The most frequently identified factors contributing to nosocomial infection are 
the length o f stay in nursery, low birth weight, foreign bodies (intravascular catheter, 
chest drain and endotracheal tube), nursery crowding, surgeiy and prolonged 
treatment with broad spectrum antibiotics. The number of bacteria on the skin surface 
will determine the probability and degree o f contamination o f the catheter at the time 
o f insertion. Local immune defences are more likely to be overcome when large 
numbers o f bacteria are present on the skin at the catheter insertion site.
Many strains of coagulase negative staphylococci produce a complex 
mucopolsaccharide which has been termed extracellular slime substance. Electron 
microscopy studies suggest that it stabilises the attachment of coagulase negative 
staphylococci to the surface o f foreign bodies such as intravascular catheters. 
Extracellular slime substance has been reported to have a number of 
immunomodulating effects such as inhibiting antibody binding the staphylococcal cell 
wall, reducing the chemotactic response o f neutrophils and interfering with T and B 
cell function. Although extracellular slime substance is probably important in
stabilising the attachment o f bacteria on surfaces, its importance in determining 
pathogenicity is controversial.
Gram positive organisms (S. aureus, S. epidermidis, group D streptococci) 
account for 56% o f nosocomial sepsis whereas gram negative bacteria represent 25% 
and Candida species another 13%.
" i iI
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1.5 Pathogenesis of bacterial infection
In utero the fetus lives in a sterile environment and becomes colonised and
.occasionally infected when he/she comes into contact with vaginal flora. During the 
postnatal period the neonate may acquire infection from various sources including
■r-
.hospital staff, mother and other infants, and exposure to equipment heavily 
contaminated with bacteria. Equipment requiring humidification such as incubators or 
respiratory equipment is commonly contaminated with water loving organisms.
Techniques that have proved life saving for sick or small neonates may also increase 
the risk o f infection by breaching the mucocutaneous barrier to infection.
There are three lines of defence mechanisms that protect the infants from
infection. %
1.5.1 Physical defence systems
At the surface o f the body and within body cavities that communicate with the 
surface (respiratory tract, genitourinary tract and gastrointestinal tract) there are 
anatomic barriers and fluids that inhibit attachment and invasion o f organisms. Among
these the skin is the greatest natural barrier to infection. Exclusive of the resident,
.....
commensal bacteria, most micro-organisms are inactivated by material on the skin
%
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surface such as fatty acids. During the neonatal period, the skin is functionally and 
anatomically immature, permeability is increased and there is increased susceptibility 
to blister formation in the neonate^^^l
The pH o f the skin is higher during the first few days o f life than in the older 
child or adult^^^ .^ Quantitatively the skin surface lipids are similar to those in the older 
cliildren. However during the first two weeks of life cholesterol is decreased and wax 
esters increase. The skin's free fatty acids and triglyceride slowly decrease during the 
post natal period^^'^l Postnatally, the skin o f the new-born infant becomes extensively 
colonised, and breaks in the skin integrity (scalp sampling, umbilical catheterisation 
and forceps trauma) may allow the micro-organisms to enter the body, thus 
increasing susceptibility to infection. The umbilical cord, provides an excellent 
medium for bacterial growth and acts as a potential source o f sepsis due to its 
proximity to the blood stream.
Immature gastrointestinal host defences may permit aberrant bacterial 
colonisation resulting in inadequate neutralisation o f bacterial toxins and allows 
bacteria and toxins to gain access to intestinal tissue. New-born infants and especially 
preterm infants have lower rates o f gastric acid secretion than older infants. Such 
hypochlorhydria is associated with bacterial colonisation of the stomach in the 
majority of enterally fed preterm infants^^^’^ ^l Gastric acidity provides the first line of 
defence against bacterial colonisation o f the upper gastrointestinal tract. A relatively
■■
high gastric pH may also inhibit protein digestion and permit the passage o f intact 
molecules into the small intestine^^^l Proteolytic enzymes produced by the pancreas 
probably play an important role in limiting the exposure o f the small intestine to toxins 
and other intact protein molecules. New-borns have a much lower level o f tiyptic 
activity in their intestinal fluid than older infants^^^^ resulting in impaired protein
ÏI
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digestion and bacterial toxin destruction. There is also reduced biosynthesis o f bile 
acids in the new-born which has an important antibacterial implication.
Poor intestinal motility may also lead to stasis and bacterial over-growth. 
Duodenal peristaltic patterns are markedly immature until approximately 29 weeks 
gestation after which they begin to assume more mature patterns^^^l New-born infants 
also have specific gastrointestinal immunological deficiencies including a reduced 
number o f T cells in their intestinal mucosa. This results in an inability to destroy 
infected intestinal epithelium cells. Stool levels o f IgA are quite low in new-borns 
compared with older infants and children^‘^ 1^ Secretoiy IgA appears to play a role in 
host defence mechanisms by complexing with antigen in the intestinal lumen, thus 
preventing its access to intestinal tissue. There is evidence that the preterm intestine is 
more permeable to carbohydrate, protein and bacteria than in older infants.
In preterm infants the development o f respiratoiy bronchioles, alveolar ducts 
and sacs is incomplete. An immature ciliary apparatus leads to sub-optimal removal of 
inflammatoiy debris, mucus and bacteria. The neonatal lungs also have an insufficient 
number o f pulmonary macrophages for intrapulmonary bacterial clearance. Other 
natural barriers to infection, including the mucociliary blanket and filtering mechanism 
o f the nose are immature in preterm infants. Many premature neonates require 
respiratory support and during this time the respiratory tract rapidly becomes 
colonised with bacteria and fungi. This results in an increased incidence of systemic 
infection. Antibodies in the secretions play an important part in protecting the infants 
from infection by preventing adherence o f antigen and by neutralising the organisms 
and their products. Foiysth et al.^ "^ ^^  have shown that the concentration o f IgA and 
IgM  in preterm infants tracheo-bronchial secretions increases with increasing post­
natal age. Intubated preterm neonates have been shown to produce IgM antibody to 
bacteria present in the lower respiratory tract. Robertson et al.*"^ ^^  suggested that very
12
preterm infants are apparently able to acquire mucosal IgA and specific antibody but 
at a lower rate than gestationally older infants. This suggests slower postnatal 
maturation o f mucosal antibody transport and production than in those born at full 
term.
1.5.2 Cellular immunity
A normal adult produces about 130 billion neutrophils per day from the bone 
marrow. Polymorphonuclear (PMN) leukocytes originate from pleuripotent stem ceils 
in the bone marrow. They begin as myeloblasts which differentiate by division into 
myelocytes in about one week. During a 7 days post-mitotic period cytoplasmic and 
nuclear changes occur that result in a fully mature and functional PMN leukocyte. The 
bone marrow stores these mature neutrophils, so that they can be called upon under 
conditions o f stress or infection. This reserve is about 13 times greater than the 
numbers o f these cells in the circulation. The PMN leukocytes acquire two major 
populations o f granules during development. The primary azurophilic granules appear 
during the mitotic period and contain myeloperoxidase, acid hydrolases, lysozyme 
cationic protein and neutral proteases. Primaiy granules are released into the 
phagosome following phagocytosis and provide the PMN with localised microbicidal 
activity.
The secondary (specific) granules are formed during the 7 days maturation 
period and contain lactoferrin, lysozyme, vitamin B12 binding protein, cytochome b, 
collagen, and certain receptor molecules. The specific granules which discharge much 
o f their contents out o f cells are thought to provide a regulatory function in 
inflammatoiy response. A third type o f granule has been identified. It contains 
gelatinase, cytochrome b, and MAC-1 glycoprotein receptors which have been 
identified as an important mediator o f adherence. Circulating PMN leukocyte
13
represent only 5% o f the body pool. Neutrophils appear to have only a veiy short half 
life o f about six to eight hours in the vascular pool. They are equally and randomly 
distributed between a population o f marginal cells which are adherent to endothelial 
layer o f blood vessels and a population o f circulating cells. When PMN leukocyte 
enter the tissue they remain functional for 1 to 2 days. Senescent PMN leukocyte are 
removed by splenic macrophages or discharged fi om mucosal surface. An increase in 
both total numbers and percentage of circulating PMN leukocyte can be induced by 
acute infection, endotoxins and steroid. This increase occurs via increased bone 
marrow production, accelerated bone marrow release and demargination. In case of 
an acute inflammation the blood flow through an area o f acute inflammation is 
markedly increased, the vascular endothelium becomes sticky and the contained 
neutrophils attack to it and then push their way between the endothelial cells. Once 
outside the capillary, the accumulation o f these cells results from their positive 
migration toward the chemoattractants like bacterial products, autologus debris, the 
cleavage products o f the third component o f complement (C3a) and the granule 
contents from mast cells.
i. Normal blood leukocytes in the fetus and new-born infant
Many studies have been done to establish comprehensive reference ranges of 
total and differential leukocyte counts in the human fetus. Davies et al.f"^ ^^  studied the 
total and differential leukocyte counts from 18 weeks of gestation to term (obtained 
from cordocentesis and elective Caesarian section). They found that the total 
leukocyte count in the fetus increased with progress o f gestation, from 2.27 x lO^/I at 
18 weeks to 9.41 x 10^/1 at 40 weeks. This increase reflects two components: a linear 
increase in the lymphocyte count from a mean o f 1.17 x 10^/1 at 18 weeks of gestation 
to 3.67 X 10^/1 at 40 weeks, together with an exceptional rise in neutrophil count from 
a mean value o f 0.77 x 10^/1 at 31 weeks to 6.53 x 10^/1 at 40 weeks. Monocyte 
number increased linearly with gestation from a mean o f 0.07 x 10 /^1 at 18 weeks to
14
0.44 X lO^/l at 40 weeks. These changes were paralleled by a reciprocal decrease in 
the erythroblast count.
No significant increase in eosinophil count was noted with progress of 
gestation. Early myeloid cells (metamyelocyte, promyelocyte, myelocyte, blast cells) 
were observed in 24% of total films and basophils in 15%. They contributed less than 
2% of the total white cell count and there was no significant change with gestational 
age.
In intrauterine life the total leukocyte count increases with gestational age until 
37-38 weeks gestation when lymphocytes predominate. However from 32 weeks 
onwards the proportion o f neutrophils increases to become the commonest leukocyte 
at term. The changes in the number o f circulating leukocytes as well as changes in 
other fetal haematological values with gestation were also noted in other studies^'‘'^ ’'*^ l 
This reflects an alteration in the pattern o f pleuripotent haemopoietic stem cells to 
meet changing fetal physiological priorities during gestation.
The placenta acts as an effective barrier to most bacteria. Therefore the 
acquisition o f a host defence mechanism directed against bacterial infection is only 
necessaiy in preparation for extrauterine life. This may explain the dramatic rise in the 
number o f circulating neutrophils during the late third trimester. After birth there are 
also some changes. Neutophil concentration is quite high at birth and may rise even 
higher during the first days o f life. By two weeks the neutrophil count declines to 
within and occasionally below normal levels.
ii. Function of PMN Leukocyte
When bacteria invade the tissue, an acute inflammatory response occurs, PMNs 
become activated and large numbers are brought to the site o f inflammation. PMNs
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adhere to the vessel wall. This is enhanced by cell surface glycoprotein then they pass 
through the capillary wall to interstitial tissue. After migration PMNs are guided by 
chemotactic agents such as C3a which is a major chemoattractant factor o f semm and 
inflamed tissue. When PMN cells arrive at the active site o f inflammation they may be 
killed by bacterial toxins or they may remain active with adherence o f bacteria to the 
cell membrane. This is followed by an ingestion process called phagocytosis (Figure 
1.1). Phagocytosis is a major defence mechanism by which the immune system 
protects the body against bacterial infection. Calcium and magnesium ions are 
required for optimal phagocytosis and anaerobic glycolysis is the energy source. The 
neutrophil has a recognition site for the organisms on the surface. Virulent organisms 
are less readily recognised and engulfed. They generally require to be coated with a 
phagocytosis- promoting opsonin like specific antibody and or C3b for which the cells 
have receptors on their surface.
IgG binds to bacteria with the Fab end following interaction between the Fc 
portion and Fc receptors on the cells. Interaction between IgG and Fc receptors opens 
calcium dependent channels that may be important in regulation of phagocytosis and 
post-phagocytic events. The PMNs membrane bulges around the particles (bacteria) 
with formation o f a phagocytic vacuole (phagosome). The cytoplasmic granules 
release their contents into the phagosome. These granules contribute to bacterial 
killing and lysis. The important event in relation to the killing system is a brief burst of 
respiratoiy activity that accompanies phagocytosis with consumption o f oxygen. In 
this process, a variety o f products o f reduced oxygen are produced like superoxide 
O2 , hydrogen peroxide (H2 O2 ) and hydroxyl radicals (HO). Hydroxyl radicals (HO) 
is the strongest oxidant known.
16
Opsonization
Serum factors
Bacterium
>V Adherence
White blood cell
Phagocytosis
Killing and digestion
Phagosome formation
Phagosome
Phagolysosome Fusion Lysosome
Figure 1.1 The phagocytic process
17
by almost 100% compared to neonatal rats who decrease their CFU-GM by almost 
50%. While during experimental bacterial sepsis in the neonatal rats, they fail to 
increase their already high myeloid progenitor proliferation nde^^  compared to the 
adult animals, but in fact they decrease their CFU-GM.
iii. Impairment of cellular immunity in neonates
The high incidence of bacterial sepsis in the new-born appears to be 
multifactorial. One o f the most important deficits in the neonatal immune system is the 
quantitative deficiency in the myeloid and phagocytic system^'^^l Additionally despite 
normally circulating numbers o f mature affected phagocytes, the presence o f serious 
(in vitro) neutrophil abnormalities may still exist and predisposes the neonate to an |
impaired immune response during overwhelming bacterial sepsis '^^ ^^
A. Neonatal myeloid progenitor deficiency
Christensen et al.^ '*^  ^ have demonstrated significant differences in the neonatal 
rat myeloid progenitor system compared to its adult counter part. Significantly the 
neonatal rat has reduced myeloid progenitor cells (CFU-GM) to 10% - 20%. By 4 
weeks o f age there is a developmental maturation of myeloid progenitor cells to 
approximately normal adult levels. Additionally it appear that neonatal rat myeloid 
progenitor cells (CFU-GM) are proliferating at a much higher rate than in adult
animals. At birth and through the first week o f life the neonatal rat myeloid progenitor 
cells proliferate at approximately 75% - 80% of maximal capacity compared to 25% 
rate in the adult rat. Similarly Christensen reported that CFU-GM proliferation rate of 
premature humans is also near maximum capacity. In the neonatal rat it takes 6 weeks 
of developmental maturation before myeloid progenitor pools proliferate at a low 
normal adult level o f 25%.
During experimental sepsis adult animals increase their myeloid progenitor pool
I
II
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After inoculation with GBS the new-born rat demonstrates substantially 
different neutrophil kinetics compared to those found in adult animals. Adult animals 
increase their circulating PMNs count by increasing their stem cell pool two to three 
times and increasing their stem cell proliferation rate by a similar amount. In contrast 
neonatal animals under the same conditions fail to increase their stem cell pool (CFU- 
GM) and may in fact decrease their pool, and also fail to increase their stem cell 
proliferation rate. This development contributes to reduced circulatory mature 
neutrophils and increased mortality during sepsis.
B. Neonatal neutrophil storage pool
The neonatal storage pool (bone marrow myeloblast, neutrophil, band cells, 
metamyelocytes) is severely reduced compared to adult animals^'^^l At birth the new­
born marrow neutrophil storage pool is approximately 25% that o f nonnal adult 
animals levels and requires about 4 weeks o f development maturation to reach adult 
levels^^^l Experimental GBS sepsis significantly alters the neutrophil storage pool in 
the new-born bone marrow compared with adult animals. Neonatal rats deplete their 
already reduced neutrophil storage pool by almost 80% from previous existing levels 
compared to a decrease o f 33% in adult rats^"^^^.Furthermore, during bacterial sepsis 
the daily turnover o f neutrophils increases dramatically as the half life of the 
circulating neutrophil decreases. In adult animals and the human being the daily 
turnover of neutrophils increases during infection from 1.6 x 10^ PMN/Kg/day to 
approximately 5 x 10^ PMN/Kg/day. This marked increase in the daily turnover of 
neutrophils during overwhelming bacterial infection leads to depletion of mature 
neutrophil storage pool cells. Therefore an adult animal can consume its entire 
neutrophil storage pool in one day during bacterial sepsis. Since neonates already have 
a compromised neutrophil storage pool, this increase in neutrophil utilisation 
contributes to the exhaustion of neutrophil reseiwes during sepsis and subsequently 
increases their mortality.
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Peripheral iieutropoenia is a hallmark finding in overwhelming bacterial sepsis in 
the new-born and is associated with a poor prognosis. The marked decrease in CPU - 
GM in the neonate, a near maximum proliferative capacity o f myeloid progenitor cells, 
an accelerated egress and release o f neutrophil storage pool cells from the bone 
marrow reserve and accelerated neutrophil utilisation during infection, all predispose 
the neonate to a significant neutropoenia. The incidence o f severe neutrophils storage 
pool depletion (<7%) associated with neonatal sepsis has varied in different series and 
ranges from 15% to 62%*^^i. The tm e incidence of severe neutrophil storage pool 
depletion associated with neonatal neutropoenia during bacterial sepsis is probably 
under In the study o f Engle et al.^ "^^  ^ it was 6%. This observation may not
be the only indicator o f a poor prognosis.
C. Physiological function of neutrophils in neonates
Over the years a number o f investigators have demonstrated significant in vitro 
function abnormalities in PMNs derived from neonates. These abnormalities have 
been found to be even more pronounced during neonatal sepsis or stress. A variety o f 
these abnormalities have been summarised recently by Hill et al.^^^l Specific defects in 
the neonatal PM N include a decreased deformability, chemotaxis, phagocytosis, C4b 
receptors expression, adherence, bacterial killing and altered oxidative metabolism^^*^l 
Socchi et al.^ ^^  ^ examine the postnatal maturation o f PMNs chemotactic ability after 
very premature birth and they found a delay in maturation of PMNs chemotaxis in 
premature babies born before 34 weeks compared with those born between 34-36 
weeks. Leonard Eisenfield Peter et al.^ ^^  ^ noted PMN chemotaxis in healthy term 
neonates was significantly impaired during the first week o f life and increased to adult 
level by two weeks of life.
Miller et al.^ ^^  ^ demonstrated impaired chemotaxis o f neonatal neutrophils in 
response to various bacterial organisms and antigen antibody complexes. Additionally
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oxidative metabolic abnormalities have been demonstrated in the PMNs o f new-borns. 
Ambruso et alJ^®' reported a decrease in the generation o f the hydroxyl radicals of 
PMN in contrast with normal to increased amounts o f superoxide generation of 
PMNs in the neonates. Bruce et al.^ *"^  ^ have recently reported impaired surface 
membrane expression o f C3bl receptors in neonatal neutrophils which have been 
implicated in the abnormal adherence o f neonatal PMNs. The adherence o f PMN cells 
is also impaired during the first pos-natal week.
A summary o f the quantitative and qualitative myeloid deficiencies obseized in 
the neonatal infant is given below:
A. Quantitative changes
1. Decreased bone marrow myeloid progenitor.
2. Decreased bone marrow myeloid proliferation.
3. Decreased bone marrow neutrophil storage pool
4. Decreased neutrophil count in septic infants..
5. Decreased myeloid response to sepsis,
B. Qualitative changes
1. Decreased deformability and chemotaxis.
2. Decreased adherence and C3bl expression.
3. Decreased opsonisation and phagocytosis.
4. Decreased bactericidal activity.
5. Decreased oxidative metabolism.
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1.5.3 Humoral immunity
a) Immunoglobulin (B lymphocyte cell)
Differentiated lymphocytes subserving antibody production are refered to as B 
cells (Bone marrow derived cells). B cells originate from a progenitor pool in the bone 
marrow, characterised by a lack or low concentration of surface immunoglobulin. B 
lymphocytes synthesise and secrete specific antibody, some o f which are incorporated 
into the cell membrane and sei*ve as receptors for antigen. This surface bound 
immunoglobulin (Sig) can be identified by a variety of techniques. Approximately 
15%-30% of normal peripheral blood lymphocytes have been found to bear Sig. 
Lymphocytes having surface IgM, IgD, IgG, IgA make up the greatest number o f B 
cells in the peripheral blood in adult. A second marker o f B cells is the Fc (ciystalline 
fragment) receptors which binds the Fc portion o f the immunoglobulin molecule. B 
cells can also be shown to have cell surface receptors that interact significantly with 
two components o f complement C3b and C3d.
I. Humoral and opsonic deficiency
Humoral immunity including quantitative immunoglobulin and opsonic activity
are markedly impaired in animals and human preterm and term neonates. Preterm 
•infants have a poor response to various antigenic stimuli, a reduced level o f gamma 
globulin at birth due to a reduced maternal supply o f immunoglobulin from placental 
transport and inability to produce their own immunoglobulin. The presence of 
physiological hypogammaglobulinaemia has been noted by several investigators in 
preterm and term neonates.
Ï
Ballow et al.^ '^  ^ have reported a reduced level o f IgG in preterm infants born 
between 26 to 31 weeks gestational age, with an increase in circulating
:
immunoglobulin levels with increasing gestational age, but the levels are still reduced 
compared with those in term infants. Almost 33% of infants with birth weight o f less 
than 1500 grams develop hypogammaglobulinaemia with IgG levels o f less than 200 
mg/dl^^^l Neonates have lower concentrations o f certain IgG subclasses including 
IgG2 and IgG4. Neonates therefore are unusually susceptible to pyogenic bacterial 
infection since most o f  the antibodies that opsonise capsular polysaccharide antigen of 
pyogenic bacteria (GBS and E. coli) are contained in these deficient IgG2. Also
neonates have low levels o f IgA and IgM due to the poor ability of those
immunoglobulins to cross the placenta.
Even during overwhelming sepsis the neonate cannot produce type specific 
antibody. During neonatal sepsis, there appears to be a transient increase in the
synthesis o f IgM but little production o f IgG^^^l This impairment in type specific
antibody production, appears to be secondary to defects in the differentiation o f B 
lymphocytes into immunoglobulin secretory plasma cells and T lymphocyte mediated 
facilitation o f antibody synthesis^‘"'^ ’'" l^ Thus reduced antibody levels in the neonate 
appear to be secondary to reduced maternal transport o f maternally derived antibody 
and impaired neonatal antibody production secondary to abnormal interaction 
between B and T lymphocytes in the neonate.
n . Structure of immunoglobulin
The antibody activity of serum and secretion is associated with a heterogeneous 
group o f proteins collectively known as immunoglobulin. Despite their heterogeneity, 
all antibodies share certain stmctural similarities. All consist o f a subunit composed of 
four polypeptide chains held together by a disulphide (Figure 1.2) bond. Two have a 
molecular weight o f 53,000 to 75,000 depending on the immunoglobulin class and are 
known as the heavy (H) chain. The other two have a molecular weight o f 22,500 and 
are known as the light (L) chain. On the basis o f their general properties, and the
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immunochemical features of their constituent H chains, immunoglobulins are 
subdivided into five major classes IgG, IgM, IgA, IgE and IgD. Within a given class 
o f heavy chain, subclasses have been distinguished by their antigenic characteristic, for 
instance there are four subclasses o f IgG.
Each H chain is joined to its adjacent L chain by non-covalent forces and a 
single disulphide bond. The two L-H chain pairs of each immunoglobulin molecule are 
also linked by non-covalent interaction and by neighbouring disulphide bonds (usually 
two) between the heavy chains. When 7s gamma globulin is treated with papain in the 
presence o f cysteine, three 3.5s fragments will result. Two of these are 
identical , consisting of a light chain and the amino-terminal o f the heavy chain (Fc 
fragment o f heavy chain). These are referred to as the Fab (antigen binding) fragment. 
The third piece is known as the Fc (crystalline) fragment. It contains the carboxy- 
terminal half o f both H chains (most o f the carbohydrate and the antigen determing 
class o f specificity). The Fc piece mediates fixation o f immunoglobulin molecule to 
cells (skin, mast cells, lymphocyte and macrophage), placental transfers and 
complement fixation.
1. Immunoglobulin G (IgG)
IgG is the major immunoglobulin in man and constitutes about three quarters of 
the total gamma globulin. The semm concentration varies from 800-1600 mg/dl in 
adults but the intravascular pool accounts for less than half o f the total body IgG. 
About 55% is found widely distributed within the extravascular space. Also it is 
present in external secretions and cerebrospinal fluid. Its molecular weight is 155,000 
and it is synthesised at a rate o f 33 mg/Kg/day. The total body content is in excess of 
Ig/Kg o f body weight. IgG molecule has a half life o f about 21 days and thus it is the 
longest lived immunoglobulin. On the basis of antigenic determinants within heavy
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Figure 1.2 The IgG molecule. Antibodies of the IgG class contain four chains o f 
amino acids linked by disulfide bonds. The Fab (fraction antigen binding) and the Fc 
(fraction crystallizable) portions mediate various immunologic function.
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chains of IgG, four isotype subclasses of IgG molecule have been identified in the 
serum. IgG i consists o f 66% of total IgG, IgG 2  (23%), IgGs (7%) and IgG4 
(4%)[^^l
These antigenic differences are the result of a variation in amino acid sequences 
of carboxyl-terminal parts o f the gamma chain. All four types o f molecule are found in 
any given normal serum. In addition to the antigenic difference that determines 
immunoglobulin subclass, the protein within each IgG subclass possesses distinctive 
allotype antigen known as Gm factor. These factors are the products o f allelic genes 
that are associated with the separate ciatrous controlling each immunoglobulin 
subclass. IgG4 subclass has no recognised Gm marks. Some biological properties of 
IgG proteins and particularly those mediated by the Fc fragment are distinctively 
subclass specific.
The complement activation through binding o f C lq  (the first activated 
component o f complement) is most efficient with IgG l and IgG3. IgG2 is also active 
but intact IgG4 is completely i n a c t i v e T h e  binding o f IgG to macrophages and 
granulocytes Fc receptors is most efficient with IgG l and IgG3^^^’^ ^^ - The later 
reaction is important in opsonisation. M ost o f the antibodies developing in response 
to antigen stimulation are IgG. It is the only immunoglobulin selectively transferred 
across the placenta, thereby giving a measure o f protection to the new-born 
infants^ ^^ '^ ]^. ■i
Dimitris Sideropoulos et al.^ ^^  ^ studied the transplacental passage o f IgG in the 
last trimester o f pregnancy. Intravenous immunoglobulin (IVIG) in combination with 
antibiotic (amoxicillin and clindamycin phosphate) was given to 27 pregnant women 
at 27 to 36 weeks with signs of chorioamnionitis who were at risk o f preterm delivery. 
IVIG was given either as a single dose o f 12 grams in 12 hours (low IVIG dose) or 24
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igrams on each o f 5 consecutive days (high IVIG dose). 24 patients received the same 
antibiotic alone (control group). IgG concentration in maternal and umbilical cord 
sera were measured and the levels o f four IgG subclasses were determined.
They found transplacental passage of IVIG was shown to be a function o f 
gestational age and o f dose. Up to 32 weeks of gestation, IVIG infusion has no effect 
on IgG concentration in cord serum. After that time cord serum IgG levels were 
significantly higher in the high dose group compared with low dose and control 
group. All four subclasses o f IgG and two different antibodies present in the IVIG 
preparation passed from the mother to the fetus. Thus the infused IgG mimicked the 
transplacental passage of endogenous IgG. The semm IgG concentration at different 
gestational ages, in neonates and infants are shown in Table 1.1.-Figure 1.3.
Smith and Hammarstram^^'^J also demonstrated that the subclasses IgGi, IgG2,
IgGs were transferred from the mother to the fetus. Boyers et al.^ ^^  ^ investigated the
transfer o f endogenous IgG to GBS type la  antigen in paired maternal and cord sera.
Nearly all GBS can be identified and classified into five distinct serotype (la, Ib, Ic, II,
III) based on the presence o f type-specific capsular polysaccharide and protein 
.antigens present on the cell surface. The presence or absence o f type-specific antibody 
to these antigens appears to correlate with relative risk of developing invasive disease.
The ratio of cord/ maternal anti-la concentration increased with an increase in 
gestational age from 0.33 at 28 weeks gestation to 0.49 at 40 weeks of gestation.
These kinetics o f the passage o f anti-la antibodies were similar to those observed for 
non-specific endogenous IgG^^^'^^l Physiologically this transfer o f IgG antibody is 
mediated by an active transport mechanism^^^^ and appears to be initiated by receptors 
at the syncytiotrophoblast membrane that binds the Fc portion o f IgG molecule.
■
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Biological properties of IgG
M ost antibodies developing in the secondary response to antigen stimulation are 
o f the IgG type. Some biological properties o f IgG are distinctly subclass specific.
Complement activation is most efficient with IgG l and IgG3. IgG2 is also active but 
intact IgG4 protein is completely inactive.
The binding to macrophages and granulocyte Fc receptors is most efficient with 
IgG l and IgG3. The latter reaction is important in opsonization. IgG3 has shown a 
great tendency to aggregation, which is probably involved in its affinity for C lq. In 
addition, IgG3 is selectively retained in the sera o f a number o f patients with 
generalised hypogammaglobulinaemia. IgG antibodies are efficient in the 
neutralisation o f some toxins and vimses through Fc fragment.
The activation o f complement through binding to C lq  (the first activated 
component o f complement) depends upon changes in configuration of antibody 
molecule when they are brought into close apposition during reaction with antigen
.
and it is the Fc fragments o f the heavy chain which carries the predominant part o f the 
molecule responsible for complement fixation.
v : |
2. Immunoglobulin A (IgA)
The IgA antibodies can be divided into two separate systems of 
immunoglobulin. One o f these provides IgA antibodies for the circulation and the 
internal secretions such as aqueous humour o f the eyes, the cerebrospinal fluid, 
synovial fluid, amniotic fluid, pleural fluid, and the peritoneal fluids. It is likely that 
these IgA antibodies are synthesised by nonmucosal lymphoid tissue^^^l The other 
system o f IgA antibodies is found in external secretion such as saliva, tears, bile and 
colostrum as well as those o f the respiratory tract, gastrointestinal tract, seminal
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vesicle, cervix, and the urinary tract. The IgA o f external secretions is not derived
from blood but produced locally by plasma cells situated in proximity to the epithelial
in the infant by 15 days postnatally in most infants at a level o f 1-5 mg/dl. Its 
concentration increases gradually with age to reach levels approximately 30 mg/dl by 
6 months (Figure 1.3).
About 1% o f immunoglobulin is secretary IgA^’^l The proportion o f secretoiy 
ncreases in a variety o f mucosi 
with a molecular weight o f 390,000.
mucosa^^^l It is the predominant immunoglobulin in external secretion, although 
smaller amounts o f IgM and IgG may also be found. In the serum 85% of IgA 
molecules are monomers with a molecular weight o f 170,000 and the serum IgA 
concentration is in the range o f 200-300 mg/dl with a half life o f 6 days^^^l 42% of
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IgA is intravascular, and its synthesis is at a rate of 24 mg/Kg/day. It is not transferred 
across the placenta.
Intrauterine synthesis (Table 1.1) is very minimal and it becomes detectable
I
IgA i al inflammatoiy diseases. It has a large molecule
Biological properties
.Secretoiy IgA is reported to be active against a variety o f viruses and bacteria 
but the mechanism is u n k n o w n I  IgA is incapable o f fixing complement or acting 
as an opsonin. Although IgA does not activate complement by the classical pathway, 
it can be shown to have activity in the alternative complement pathways^^^l Like other 
immunoglobulins, secretory IgA is capable of blocking bacterial adherence to mucosal 
surfaces, thereby preventing colonisation. It may also act as a backing antibody to 
reaginic reaction on mucosal surfaces and may prevent the absorption o f antigenic 
molecules from the lumen o f the gut^^^l
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Table 1.1. Levels o f immunoglobulins (mg/dl) in sera of fetus, new-born and infants 
by age^ °^ .^
Age ..................IgG ................. IgA IgM
-23 weeks below 100 —
“(13-14) weeks 330+31 — —
-(7-8)weeks 456+107 --- —
-(3-4) weeks 823+135 --- —
At term 1031+200 2+3 11+5
1-3 Months 430+119 21+13 30+11
4-6 Months 427+186 28+18 43+17
7-12 Months 661+219 37+18 54+23
13-24 Months 762+209 50+24 58+23
25-36 Months 892+183 71+37 61+19
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Figure 1.3 Development o f immune globulin (mean levels o f immune globulin in 
mg/dl) (Richard V et al. Immunology in the paediatricians office. Clinical Immunology 
41;4;691-713,1994)
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3. Iminunoglobulin M (IgM)
IgM  antibodies have a molecular weight o f 850,000. Because o f their size IgM 
molecules are refererd to as macroglobulins. Their rate o f synthesis is 6.7 mg/Kg/day 
which is only 1/20 that o f IgG whereas their fractional catabolic rate is two to three 
times higher than that o f IgG^^^l This accounts for a relatively short half life o f about 
5 days and low semm levels o f 80-300 mg/dl^^^l IgM can be detected in cord blood 
after 30 weeks o f gestation and increases veiy slowly with gestation, reaching 10 
mg/dl in full term infants with an upper limit o f normal ( ± SD) o f 20 mg/dl (Figure 
1.3-Table 1.1). The IgM molecule consists o f five subunits, each with two antigen 
combining sites. There are 10 antigen combining sites per IgM  molecule especially if 
the antigen is relatively small. 75% o f IgM is intravascular. IgM is present in external 
secretions but not in the cerebrospinal fluid.
Biological properties of IgM
Macroglobulins (IgM) are restricted predominantly to the intravascular poof^^l 
Little if any IgM crosses the placental barrier and that present at birth is 
predominantly o f fetal origin. Detectable levels o f IgM may be synthesised by the 
human fetus as early as the twentieth week o f gestation^^"^ ,^ but high levels o f IgM at 
birth are usually an indication o f intrauterine infection. Specific receptor sites on 
macrophages for the Fc region o f IgM have been identified in animal systems^^^l Such 
receptors may play a critical role in the phagocytosis o f immune complexes. IgM 
antibodies are the first to be produced in a primaiy immune response and to be
replaced subsequently by IgG antibody. In addition however certain types o f antibody 
response remain predominantly IgM  including those against lip op oly saccharide 
antigen.
i
a
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4. Immunoglobulin E (IgE)
Reagenic antibodies which mediate acute and sometimes life threatening allergic 
reactions in atopic patients belong to this distinct immunoglobulin group. It has a 
molecular weight o f 200,000. Their survival in the serum is shorter than that o f any 
other immunoglobulin (half life is 2.4 days). Serum concentration is in the range of 
0.01-0.07 mg/dl with a mean o f 0.03 mg/dl^^^'^^l Higher concentrations may be found 
in the semm of patients suffering from asthma, hay fever, eczema and helminthic 
infestation. 50% of IgE is intravascular and is synthesised at a rate of 0.02 
mg/Kg/day. It is present in external secretions, but not in cerebrospinal fluid. IgE 
forming plasma cells are most frequent in the respiratory, gastric and intestinal 
mucosa and in the regional lymph nodes but few are found in the plasma and other 
lymph nodes. IgE like IgA is classified as a secretoiy immunoglobulin.
Biological properties
IgE antibodies are capable o f sensitising basophil and mast cells. The Fc portion 
o f the IgE molecule fits into specific receptor sites in the cell suiTace^^^ .^ When 
bivalent or multivalent antigens bind to at least two adjacent molecules, the mast cell 
or basophil cell is triggered to de-granulate, thereby releasing vasoactive substances 
especially histamine and slow reacting substances. These are responsible for clinical 
manifestations such as wheel and flare reactions, bronchospasm, small vessel 
dilatation and shock. IgE may also play a part in normal body defence mechanisms, 
and has a property o f complement fixation through classical and alternative pathways.
5. Immunoglobulin D (IgD)
IgD is found in low concentration in normal semm 0.3 - 40 mg/dl^^^l It has a 
molecular weight o f 180,000, and is synthesised at a rate o f 0.4 mg/Kg/day, its 
fractional catabolic rate (% per day) is 37 and it has a half life o f 2.8 days^^^l It is 
confined largely to  the intravascular space (75%) and it does not cross the placental
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barrier. IgD has been shown to be a major surface immunoglobulin o f peripheral 
blood lymphocytes^^^^, and it activates complement by classical and alternative 
pathways.
b) Fibronectin
Fibronectin is a multi-functional high molecular weight glycoprotein that sei*ves 
to facilitate cell-to-cell and cell-to-substratum adhesion. It exists in soluble and 
insoluble forms. Soluble forms are found in interstitial fluid while insoluble ones are 
present in most extra-cellular materials and are widely distributed in connective tissue 
thi'oughout the body. Fibronectin displays individual binding sites for some molecules 
such as actin, complement C lq , semm amyloid P, ganglioside and has multiple 
binding sites for other compounds^^°^, such as heparin, fibrin and immunoglobulin G. 
Multiple species o f bacteria (gram positive and gram negative) including potential 
neonatal pathogens such as staphylococci and streptococci also bind to fibronectin. 
Human adult plasma fibronectin concentration varies from 260 to 450 ug/ml. Women 
have a slightly lower level.
The circulating plasma fibronectin concentration in human fetal cord plasma is 
120 ug/ml versus 220 ug/ml in the term infants^^^l Premature infants of 30 to 31 
weeks gestation have a plasma concentration o f 152 ± 34 ug/ml, which is significantly 
less than in the term infant*^^ l^ The fractional synthetic rate (percentage o f plasma pool 
produced daily) o f plasma fibronectin varies from 9% to 31% in infants born at 26 to 
32 weeks gestation when measured before 12 days o f age^^^l In adult humans it is 
35% with a circulating half life o f 47 hours^^^l A significant correlation exists between 
the fractional synthetic rate and gestational age. Youngest infants have the lowest 
synthetic rate and the longest measured plasma half life is 7.5 days. Thus lower 
plasma levels may be related to decreased hepatic synthesis o f  this glycoprotein.
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Plasma fibronectin decreases in new-born infants and adult subjects during bacterial 
infection^^"^ .^ This may be due to a decreased synthetic rate or redistribution of 
fibronectin from intravascular to extra- vascular compartment or due to an increased 
consumption o f fibronectin in response to increased clearance o f products o f the 
inflammatory response.
Biological properties
Fibronectin plays an important role in directing cell migration, proliferation and 
. . .differentiation. It is therefore essential during embiyonic development. These 
glycoproteins perform additional integral functions during homeostasis, 
immunological clearance o f injured tissue and antibody coated micro-organisms. It 
plays a key part in maintenance o f vascular integrity. In certain pathophysiological 
conditions such as sepsis, multiple organ dysfunction, thrombosis, cancer, arthritis and 
fibrosis, the normal stmcture, physiology and function o f fibronectin may be altered 
and in many cases these changes have been implicated as contributing factors to the
A
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underlying disease. Fibronectin also plays an important part in defence against ;
infection by mediating macrophage particulate endocytosis^^^* and polymorphonuclear 
leukocyte phagocytosis^^^l
.It acts as a potent chemoattractant for monocytes and neutrophils in the
presence o f hyaluronic acid. It also enhances secretion o f interleukin-1, and the
interaction between phagocytes and the opsonised bacteria. It increases bactericidal
activity o f macrophages by increasing the affinity, distribution and activity of
phagocyte cell surface immunoglobulin (Fc) and complement C l, C3 receptors. In
summaiy fibronectin clearly seiwes to enhance the function o f phagocytes as they
..................................react to defend the host from local or systemic microbial invasion or to remove the 
debris o f cellular material at the site o f tissue injury.
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Potential adverse effects o f  a decreased concentration during an infective
episode include delayed clearance o f infection due to decreased opsonisation,
impaired neutrophil migration, phagocytosis, localisation to the site o f infection and a
decreased rate o f clearance o f products o f bacteriolysis. In addition its deficiency may
contribute to the development o f capillary leak, shock, formation o f pulmonary
.oedema and disseminated intravascular coagulation. Some workers have reported an 
improvement in immune function after fibronectin transfusion in adults with major 
illness or trauma*^^^. Jacobs et al.^ ^^  ^ have reported that neonatal cord blood 
monocytes ingest greater numbers o f GBS in the presence o f fibronectin and 
intravenous immunoglobulin. GBS ingestion by neonatal cord blood monocytes is less 
effective when organisms are pre-inoculated with type specific antibody alone, 
fibronectin plus adult serum, or semm free medium alone.
c) Complement
The complement system is composed o f a series o f glycoproteins that circulate 
in the blood and participate in many antibacterial mechanisms, such as opsonisation 
and bacteriolysis o f many pathogenic organisms^^^l There is little placental passage o f 
complement protein which has been identified in fetal tissue by six weeks gestation. 
Fetal synthesis o f  C3, C4, C5 by multiple tissues starts between the 8th and 11 th week 
of gestation. Complement synthesis preceeds immunoglobulin synthesis in fetal tissue, 
suggesting that complement is a more primitive defence mechanism. The first 
component of complement which is essential for recognition o f the tertiary structure 
alterations o f IgG  and IgM is produced by the spleen early in fetal life and also by 
tissue macrophages which are increased through gestation. The fetal serum 
complement concentration correlates directly with gestation age. In adults, 
hepatocytes appear to be the principal cells that synthesise complement. Macrophages 
and fibroblasts also may produce certain complement proteins. In the serum of 
neonates, the concentration o f most complement components is approximately 50%
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o f that observed in adult semm. For such components, as C8 and C9, the 
concentrations in neonatal semm are only 10% to 25% of the concentrations observed 
in adult semm. The semm C3 is much greater than any other component. Compared 
with the normal adult semm C3 level o f 150 to 500 mg/dl, normal cord C3 level is 
110 mg/dl. There is a rapid increase in complement levels postnatally, so that by 3 to 
6 months o f age semm levels are equal to those in adults.
Semm factors necessaiy for activation o f complement are also decreased in the
neonate. Factor B ( an acute phase protein which acts as one o f the humoral factors)
is present in the semm of the flill term neonate at levels o f approximately 50% of
maternal semm, and is much decreased in preterm infants in which there is a positive
correlation between semm level and gestational age. Factor B is essential for activity
o f the alternate complement system. Complement is required for the activity o f many
circulating antibodies and it has been demonstrated that deficiency or consumption of
this system contributes to enhanced neonatal susceptibility to infection. The
complement system has multiple functions in host defences against invading microbes
such as recognition, chemotaxis and opsonization. C l is a complex molecule
. .consisting o f three proteins C lq, C lr  and C l s. The C lq  subunit is the recognition unit 
o f complement that bears the combining site for the Fc fragment o f immunoglobulin 
and initiates a cascade by reacting with IgG or IgM antibodies that have combined 
with antigen or have been aggregated by other means. The reaction requires either 
two IgG molecules that have reacted with antigen in critical proximity to each other 
or two subunits o f a single IgM molecule. Only IgG l, IgG2 and IgG3 antibodies are 
capable o f activating complement. IgG4 does not have this property.
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1.6 Breast milk
Human milk is a recommended source o f feeding. This recommendation arises 
from its nutritional benefits, contribution to host defence, and gastrointestinal trophic 
aspects as well as psychological benefits. The most important aspect of human breast 
milk's benefit as a natural broad-spectmm, anti-infectious agents was based on the 
presence of secretory immunoglobulins in colostmm and milk, the presence o f cells 
that could participate in host defences (macrophages, PMN, lymphocyte), 
complement components, interferon, the presence of microbial growth factors that 
might allow selective growth o f nonpathogenic bacteria, and the presence o f secretory 
molecules that have antibacterial activities (lactoperoxidase, lactoferrin, lysozyme).
All o f these factors may affect the host defence o f the LBW i n f a n t s ^ T h e  
quantity o f host defence factors per unit volume in premature milk is greater than that 
in term milk^^^^l Narayanan^^®^^ reported a lower incidence o f infections in LBW 
infants fed their mother's milk during the day time compared with similar infants fed 
formula only. Another study^ ^®^  ^shows fewer LBW infants fed human milk developed 
NEC than similar infants fed formula exclusively.
The predominant human breast milk immunoglobulin is secretoiy IgA, which is
synthesised and stored in the breast, reaches levels as high as 5 mg/ml in colostrum
and decreases to 1 mg/ml in mature milW^ '^^l Secretoiy IgA acts on the intestinal
mucosal surface, resisting breakdown by gastrointestinal fluid, and blocks adhesion of
potential pathogens. Levels o f secretory IgA against specific pathogens increase in
.response to maternal exposure to these antigens (environmental specific). This gives 
the infants access to antibodies directed against specific pathogens and provides 
protection when his or her immune response is not fully developed^^^^l The 
antibacterial effects o f IgA may be amplified through the alternative pathway of
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complement activation. Breast milk contains important components o f the alternative 
pathways i.e., factors B and C3.
Mononuclear phagocytic cells are present in large numbers in human milk. All 
reagents necessary for an effective phagocytic system are present in breast milk. 
Lymphocytes are also present in human milk at a concentration o f about 200/ml, and a 
sub-population o f these lymphocytes produce interferon, macrophage migration 
inhibition factor and IgA.
Human milk contains lactoferrin and folate-binding proteins that restrict the 
availability of iron and folate to potentially pathogenic enteric bacteria and fungi. Milk 
lactoferrin is b a c te r io s ta t ic ^ ra th e r  than bacteriocidal in vitro. It has a strong 
bacteriostatic effect on E. coli and staphylococci. The highest levels o f lactoferrin are 
found in colostmm and it persists in human milk throughout the first year.
Lysosome provides a non specific protective factor. It is though to influence the 
flora o f the intestinal tract, possibly by killing pathogens through cell wall lysis. Breast 
milk has a specific factor that encourages the growth o f lactobacillus bifidus, wliich 
inhibits certain pathogenic bacteria such as Staphylococcus aureus, shigella and 
protozoa. This growth factor is stable even when milk is frozen or heated. By one 
month o f age, a breast fed infant's bifidobacterium level is 10 times that o f a formula 
fed infant's, the gram negative population being kept low by lysosome and 
lactoferrin^^^ l^
1.7 Immunoglobulin preparations
Early human immunoglobulin was adminstered by an intramuscular route but its 
use was limited by painful injections, development o f a sterile abscess at the injection
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site, local nerve damage or tissue necrosis. The efficacy of these preparations was 
reduced by low dose, slow absorption, delayed serum peak, local degradation o f IgG 
at the site o f injection and spontaneous activation o f co m p l e me n t s ^ .
Intravenous injection o f early human IgG preparations was complicated by 
severe allergic reactions, possibly due to activation o f complement by IgG 
aggregation, which limited its use, Further purification of human immunoglobulin 
permits the administration o f greater amount o f antibody with limited anaphylactic 
reaction.
Currently, there are multiple preparations o f human immunoglobulin which have 
been proven to be safe in use, and may reduce the incidence o f bacterial infection 
among patients with defective immune defence mechanisms. IVIG have been 
proposed to be effective for the treatment or prevention o f bacterial infection among 
high risk patients with congenital or acquired immune-deficiency states. Currently, 
there are three different types o f immunoglobulins which acts as an effective source o f 
antibody.
Standard IVIG is obtained from pooled human plasma and contains antibodies 
reflecting those in the age-matched general population and therefore may have 
deficiencies in antibody against some unusual micro-organisms.
Hyperimmune globulin is prepared by immunising humans against the whole 
bacteria or a bacterial antigen or obtained from patients known to have a high titer o f 
antibody against a particular pathogen. Passive immunity obtained from these 
preparations is directed against the specific infection and may include antibody to 
GBS, varicilla-zoster virus or hepatitis B virus.
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Monoclonal antibodies are the most specific immunoglobulin preparation 
available and are produced by mouse-myeloma cell lines, or by human hybridoma 
cells, resulting in a chimeric antibody o f human Fc and mouse Fab immunoglobulin. 
Mouse monoclonal antibody therapy has been limited by the development o f human 
antimouse antibody formation.
The most available preparation used for prevention or treatment o f bacterial 
sepsis was standard immunoglobulin. Pooled IVIG obtained from healthy adult 
donors may not contain functional antibodies to age specific pathogens such as group 
B streptococci and Escherichia coli and this may result in lot to lot variation in 
effectiveness. Certain IVIG preparations may have lower titers o f functional antibody 
as determined by functional assays (opsonisation) when compared to non functional 
assays such as ELISA.
Highly purified human immunoglobulin has been available since the last decade. 
Sandoglobulin is one o f the most widely used in Europe. It is a Swiss Red Cross 
pooled polyvalent IgG concentrate produced by alcohol cryoprecipitation and mild 
acidification at pH 4 from plasma known to be negative for hepatitis B antigen and 
antibodies to HIV.
Gammagard intraglobulin and Venogamma polyvalent are also IgG concentrates 
made by ethanol fractionation o f plasma. An IgM enriched immunoglobulin has 
recently been developed.
1.8 Preparation characteristics and pharmacokinetics of IVIG in low birth 
weight infants
Current preparations o f intravenous immunoglobulins are all derived from large 
pools o f plasma obtained from thousands o f donors. The preparations are initially
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fractionated by a Cohn cold ethanol fractionation process. These processes render the 
products free from viruses such as hepatitis B and HIV which have not been 
transmitted by current IVIG p r e p a r a t i o n s ^ C u r r e n t  preparations have proved 
extremely safe and effective in the management o f antibody deficiency syndromes. 
This acceptability has led to use o f high doses of IVIG in a variety o f other conditions 
including Kawasaki syndrome and immuno-thrombocytopenic purpura. In most 
commercial IVIG preparations, the IgG is further purified by ion exchange 
chromatography. M ost preparations are available as lyophilised powders that are 
stabilised by the addition o f sugar such as maltose or sucrose. IVIG is generally 
administered as 5% or 6% solution, although in some instances 10% may be 
administered.
Although the large donor pools should provide antibodies against a wide range 
of pathogens, specific antibody titres are not standardised. Titres against those 
pathogens that particularly cause problems in the neonate, such as type III GBS and 
cytomegalovirus, show considerable variation not only between the preparations o f 
different manufacturers but also between different lots from the same 
manufacturer^^^^]. An in vitro^^^^  ^ study o f one IVIG preparation showed that IVIG 
can increase the opsonophagocytic activity o f cord serum for Staphylococcus 
epidermidis which is an increasingly important neonatal pathogen. Although most 
preparations contain an amount o f IgA, which may cause an anaphylactic reaction in 
sensitised adults, this has not been reported in neonates, probably because IgA does 
not cross the placenta.
In the animal studies, the administration o f IVIG accelerated the egress of 
neutrophils from the bone marrow, enhanced the migration of neutrophil to the site o f 
infection, hastened recovery from the infection and thereby prevented neutropenia and 
depletion o f the neutrophil pool.
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Several investigators have studied the pharmacokinetics o f IVIG in neonates. It 
fits into a two phase disappearance cuiwe. The first alfa phase is short, beginning 
immediately after the infusion is administered, lasts 1 to 4 days and may represent 
redistribution of IgG between intravascular and extravascular spaces^^^^l The serum 
IgG levels decline by 20% to 30% o f post-infusion peak levels by 24 hours after an 
infusion and up to 50% 3 to 4 days post-infusion.
Noya and colleagues^^^^’^ ^^  ^ observed a 40% decline in serum IgG levels within 
one day o f IVIG inftision among very low birth weight infants. This is in part due to 
extravascular distribution and clearance o f denatured or aggregated IgG.
The second component is the beta half life, representing the catabolism o f IVIG.
This is linear and may be a better determinant of the required dose and dosing interval 
to maintain therapeutic serum IgG levels. The kinetics of IVIG in neonates as 
measured by the half life o f semm IgG level, are quite variable and difficult to 
p r e d i c t S e r u m  half life is altered by gestational age, postnatal age, the presence 
or absence of infection, the level o f total semm IgG and may even be altered by IIantibody- pathogen spe c i f i c i t y^ ^ I n  new-born infants additional factors affecting
3%
pharmacokinetics include the dose o f IVIG used, metabolic rate, functional activity of
Ïthe IVIG and the size o f the extravascular space. The combination o f all o f these I:factors leads to a wide range of semm half lives which varies from 13 to 31
d ^ s[llU 12 .114]
More recent studies^^^^’^ "^^  ^ in babies with a birth weight less than 1000 grams
i
showed that the dose of IVIG infused into these infants may be considerably larger ê
than in normal adults and also may be extremely variable. Even relatively large doses 
o f IVIG may not give the expected increment in semm IgG level. For example the 
administration o f 500 mg/Kg body weight (a relatively large adult dose) is unlikely to 1
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give satisfactory increments in the serum IgG levels in VLBW infants, and may not 
sustain satisfactoiy IgG levels for 14 days. In addition the half life o f IVIG given soon 
after birth to VLBW infants may be shortened although this appears to normalise 
rapidly with post-gestational age^^^^l For these reasons initial infusions o f 700 mg/Kg 
are recommended for babies with birth weight under 1000 grams and initial infusions 
o f 500 mg/Kg are for babies weighing 1000 grams to 1500 grams.
For optimal use o f IVIG, dosage should be calculated on an individual basis. 
Serum IgG should be checked 48 to 72 hours after the initial infusion, allowing for the 
IVIG to equilibrate between the extravascular and intravascular compartments and 
again 14 days later.
1.9 Side effects of IVIG
In adults and older children many adverse reactions have been reported in 
association with the administration of IVIG, including volume overload, hypertension, 
hypotension, headache, flushing, fever, chest pain, bronchospasm, anaphylaxis, 
laryngeal oedema, haemolysis and asymptomatic hepatitis The adverse eftects 
were common in early experimental IVIG preparations and may have been due to 
aggregates o f IgG that could activate complement and cause release o f other 
inflammatory mediators by cross-linked Fc receptors o f phagocytic cells, resulting in 
signs and symptoms associated with anaphylactic reaction. Current IVIG could cause 
similar reactions. The mechanisms are similar but are caused by antigen-antibody 
complexes that form rapidly when large amounts of antibody come in contact with 
the antigen load o f an established infection^^^^l Clinically important haemolytic 
reactions caused by antibody to blood type antigen appear to be extremely rare with 
low doses o f IVIG therapy. A true hypersensitivity reaction may produce anaphylaxis 
or milder allergic reactions which may be due to the development o f IgE anti-IgA
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is a fear but it is an extremely rare event. HIV and hepatitis B have not happened after 
the use o f IVIG. However a few reports o f non A non B hepatitis (hepatitis C) have 
been published following the use o f IVIG preparations prepared and used in 
Europe^^^"^  ^ but this has not been reported in the United States. In most centres all 
donated plasma fi*om which IgG is derived is tested for known infectious agents. 
Furthermore the process o f purifying IgG removes or inactivates many viruses^^^^’^ ^ l^ 
However technical errors in the production o f IgG are possible. The administration of 
IVIG to neonates appears to be safe, since significant adverse reactions were not 
observed.
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antibody in patients with the congenital absence o f IgA^^^^I Stabilisers or preseiwative 
may also cause allergic or other toxic reactions. Contamination with infective agents
I1
High doses of IVIG seem to block the reticuloendothelial system and may 
suppress immunity due to decreased bacterial clearance and survival^^^^  ^ in infected 
animals, decreased adult monocyte and neonatal neutrophil phagocytosis of bacteria in 
vitrol^^^l. There have been reports o f fatal infection in immuno-compromised adults 
after IVIG t r e a t m e n t ^ N e u t r o p o e n i a  in conjunction with reticuloendothelial 
blockade delays clearance o f bacteria such as E. coli from blood when 
reticuloendothelial blockade by itself has no effect. In a neutropenic infected adult,
IVIG infusion has been associated with fulminant fatal Candida albicans sepsis^’^ "^ !
The data from a study by Weisman et al.^ ^^ ^^  indicate that neonates may be 
particularly susceptible to the adverse effects o f high doses o f IVIG because 
neutropenia is common during episodes o f infection. Neonatal neutrophils are known
to have defects in adherence, aggregation, phagocytosis and intracellular killing. This '
.may be fiirther compounded by neutropenia during infective episodes. Although the 
exact mechanism o f the potential reticuloendothelial blockade is unknown, it may be 
mediated by Fc receptor blockade. The Fc portion of IgG appears to bind to Fc
I1
a
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receptors in the reticuloendothelial cells. IVIG contains organism-specific antibody 
directed against a wide range o f organisms (based on the experience o f the donor 
pool) but only a small portion o f the IVIG may be directed against any one specific 
organism. Large doses of IVIG may result in a relative excess o f non-specific IgG that 
blocks Fc receptors from binding specific IgG. There is delayed bacterial clearance
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Iwhich is seen 24 hours after the high doses o f IVIG were given. This immune
.suppressive effect o f high doses o f IVIG may be short lived. The study by Weisman et
al.^ ^^ ^^  speculates that high doses o f non-specific IgG may cause a blockade of
neutrophils or bacterial receptors necessary for opsonophagocytosis o f GBS.
.Monoclonal antibodies or IVIG preparation with a high concentration o f organism- 
specific antibodies may reduce the dose and the volume o f drug required and result in 
potentially fewer doses or volume related complications. :i:f'
In addition to  the reported side effects o f IVIG, other reactions are theoretically
.possible. Infusion o f IgG into neonates with E. coli sepsis could possibly induce
complement mediated lysis o f the bacteria. Rapid lysis o f bacteria may liberate
endotoxins into the systemic circulation and thereby increase the likelihood o f shock
and death^^^^’^ ^^l Also it is theoretically possible that antibacterial antibodies could
mediate tissue injuiy in the neonatal recipient. Pathogenic bacteria may express
.capsules that immunologically mimic components of human tissue, thereby impairing
recognition o f the organism by the host. For instance, from fetal and infant brain
tissue, Finne et al.^ ^^ ^^  isolated sialic acid which was indistinguishable from the sialic
.acid comprising the K1 capsule o f E. coli. Infused anticapsular antibody might bind
not only to bacteria but also to tissue o f the neonatal host and thereby mediate a
.destructive inflammatoiy reaction. IVIG did not suppress the production of 
endogenous IgG nor the expression of natural killer cells activity in premature 
neonates^
'I
There were a number o f reports o f acute deterioration in renal function and 
pulmonary toxicity following infusion o f IVIG in adults. The Scottish National Blood 
Transfusion Seiwice was notified o f  3 cases o f adult patients who developed acute 
renal failure soon after inftision o f IVIG^^^^l
A recent review reported 18 cases o f increased serum creatinine following 
IVIG^^^^ I^ nine o f whom were diabetic and seven were over 70 years o f age. The 
cause o f renal toxicity o f  IVIG remains to be determined. However it is known that 
small changes in plasma viscosity may affect capillaiy blood flow^^^^  ^ and high doses 
o f IVIG can result in increased plasma and blood viscosity^^^^l Part o f this effect is 
due to the large amount o f sugar used as a stabiliser o f the IVIG. This may explain 
why the renal toxicity is generally o f short duration and is self limiting.
Studies done on the safety and side effects of IVIG
Chirico et al.^ ^^ ^^  studied the safety and effectiveness o f IVIG for prophylaxis of 
infection in 133 high risk neonates. They did not observe any anaphylactic, 
inflammatory reactions or hepatitis after gamma globulin administration.
Von Murait et studied children 2-3 years of age who had received high 
doses o f IVIG during the neonatal period for treatment o f sepsis. They found no 
significant difference in semm IgG and IgM levels, response to vaccination nor to skin 
tests for cutaneous delayed hypersensitivity and anti IgG antibody levels. These data 
suggest that IVIG replacement therapy does not cause depression o f humoral or 
cellular immune response or abnormal sensitisation to polycolonal IgG.
The study by Noya et al.^ ^^ ^^  study included 20 neonates with veiy low birth 
weight (750-1500 grams) who received a single dose of 500 mg or 750 mg/Kg during 
the first week o f life. They found a modest decrease in haemoglobin and haematocrit
47
value which has been reported in another study^^^^  ^ and appears to be the result of 
haemodilution due to  a high protein content in the IVIG preparation used. Also they 
found a decrease in complement level CH 50 after IVIG which was followed by a 
rebound increase above the preinfusion values in many patients. These changes 
however were not associated with clinically detectable adverse effects.
Clapp et al.^ ^^ ®^  studied the administration o f IVIG for the prevention of 
infection in preterm infants with birth weight o f 600-2000 grams in an attempt to 
maintain a therapeutic serum target level o f 700 mg/dl in a double blind controlled 
trial. 115 patients were included. They observed one patient had one episode of 
transient tachycardia with a decrease in blood pressure during a single inftision. They 
did not detect any evidence o f haemolysis, nor hepatic nor renal impairment in the 
IVIG recipient. Also they found the infants in the IVIG and placebo group (albumin) 
had the same incidence o f intraventricular haemorrhage but they both had a higher 
incidence than the non-assigned group. This finding may be related to the osmolarlty 
and volume o f IVIG and albumin (placebo) infusion or may be due to the relatively 
better overall condition of the non-assigned group. Previous data indicate an 
association between intraventicular haemorrhage and hypertonic infusion only with 
rapid inftision^^^^l
Weismin et al,^ ^^ ^^  studied 735 neonates with birth weights o f 500 - 2000 grams, 
gestational age o f 34 weeks or less and age o f 12 hours or less in a multi centre, 
double blind controlled trial. The incidence o f suspected infusion-related adverse 
reactions was 0.5% and included hypotension and hypoglycaemia. Gonalez et al.^ ^^ ^^  
used IVIG in doses of 500-700 mg/Kg which was administered to term and preterm 
neonates without serious effects. In the study by Kanokaudi-Tsakalidou et 
IVIG was given prophylactically to  neonates weighing 1000 to 2000 grams at 
conventional doses o f 500 mg/Kg every 10 days, resulting in maintenance of a
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satisfactory semm levels o f IgG during the high risk period. Such treatment did not 
have a suppressive effect on subsequent semm immunoglobulin concentration. Homan 
et al.^ '^^^  ^ administered 500 mg/Kg o f IVIG to 10 acutely ill infants with proven or 
suspected sepsis and to 10 clinically well preterm infants less than 1750 grams birth 
weight as prophylaxis for infection. There was no incidence o f hypersensitivity, 
inflammatory or toxic reactions as assessed by changes in the physiologic and 
laboratory parameters studied.
These studies suggest that any short term toxicity o f IVIG in neonates is 
minimal. All studies agreed that IVIG infusion was well tolerated by very low birth 
weight infants. Non o f these studies however addressed potential long term adverse 
effects.
1.10 Review of studies for use of intravenous immunoglobulin (IVIG) 
for treatment of neonatal infection
Sidiropoulosl*'^^" '^ '^^! in was the first investigator to report the use o f IVIG to 
treat established bacterial sepsis in human neonates. The study was randomised, but 
not blinded and placebo was not given.
Eighty two neonates with suspected sepsis received antibiotics alone or 
antibiotics plus daily infusion o f IVIG (Sandoglobulin) for 6 days. Sepsis was proven 
in 49% and 37% of the immunoglobulin and placebo treated babies respectively. 
Gram negative rods accounted for 63% o f bacterial infection. Deaths occurred in 10% 
and 27% of immunoglobulin treated and control groups respectively. Deaths in 
infected preterm babies (<38 weeks) were 8% in the immunoglobulin recipients and 
44% o f the control group babies.
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However the administration o f IVIG was associated with a decreased mortality 
in neonates weighing less than 2500 gram at birth. This result suggests that the
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,administration o f IVIG may enhance survival in the low birth weight septic neonate.
Haque et reported a randomised, double blind, placebo controlled study
.in 60 neonates with suspected early onset sepsis treated with antibiotics for 10 days 
plus 4 daily infusion o f either 250 mg/kg/day of IVIG (5%) Pentaglobulin or 5 
ml/kg/day o f 10% dextrose. (Pentaglobin is stated to be IgM enriched). Sepsis was 
proven in 70% o f babies in the immunoglobulin group which was not significantly 
different from 77% incidence in placebo group. A large proportion o f infection were
gram negative organisms (89%). Death occurred in 5% o f immunoglobulin recipients
compared to 17% o f placebo recipients which was significantly different. This study 
concluded that IVIG enhanced the survival o f the septic neonates. I
Friedman et utilised IVIG to treat ill neonates who were neutropoenic
(WBC <3500) and whose blood contained high titers (>1:10) of group B 
streptococcal antigen by latex agglutination. This study was not randomised, blinded 
or placebo controlled. Twelve neonates with neutropoenia and high titres o f GBS 
antigen received 800 mg/kg/day Sandoglobulin in addition to antibiotic. The dose was 
repeated daily for a minimum o f four doses if neutropnia persisted, compared to 12 
patients treated with antibiotics alone. 17% o f IVIG recipients died compared to 58% 
o f control patients. This study supports the concept that IVIG may enhance survival 
in neonates with GBS sepsis, even if it has been administered after the development of
■neutropenia. In addition this study suggested that IVIG may enhance recovery from 
neutropenia although the difference was not statistically significant. Another study 
has also reported enhanced recoveiy from neutropoenia following 750 mg/Kg of 
IVIG (Gaminune-N) in neonates with clinical signs o f early onset sepsis.
*
Weisman et in a multicentre double blind randomised, placebo controlled
trial, enrolled 753 neonates o f < 2000 grams birth weight, < 3 8  weeks gestational age 
and < 12 hours old. They received a single dose o f 500 mg/kg o f IVIG 
(Sandoglobulin) or 5 mg/kg albumin. Early onset sepsis was diagnosed in 4.1% mainly 
due to GBS and E. coli. Among septic babies death occurred in 29% o f placebo 
group and none in the IVIG treated patient within the first 7 days o f life, which was 
significantly different. There was no significant difference in deaths within the first 56 
days o f life (including the first 7 days). This study suggests that IVIG may enhance 
the survival o f neonates with early onset bacterial sepsis.
Friedman, Sidiropoulos and Weisman studies suggested that there may be a 
benefit in giving IVIG but Haque did not find much benefit. These studies had a major 
design difference (e.g., non blinded investigators, small number o f patients, historical 
controls and method o f analysis). In addition the studies differed in their doses o f 
IVIG, source o f IVIG, rate and severity o f infection, and infecting organisms. 
Because o f these design difference, these cumulative data should be viewed with 
caution. These data suggest that IVIG in addition to antibiotic therapy given to treat 
neonatal infection, may be effective.
1.11 Review of studies of uses of intravenous immunoglobulin (IVIG) 
in prophylaxis of neonatal infection
Early studies on immuno-prophylaxis and therapy in neonates were carried out 
by administration o f intramuscular IgG preparation. The first study using intravenous 
preparation by Sidiropoulos^^^^^ documented a significant reduction in the mortality of 
infected preterm infants. The results o f this study encourage many clinician to utilise 
IVIG therapy.
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Haque et administered 120 mg/kg o f Intraglobulin to very low birth
weight (<1500 grams) neonates on day one o f life (50 neonates) or a similar dose at 
birth and at eight days of life to another 50 neonates. Another 50 neonates were 
untreated and served as a control. All neonates were observed for infection during 
the first 12 days. Proven bacterial sepsis developed in 4%, 4% and 16% of patients 
who received one dose, two doses and in the placebo group respectively. There was a 
reduction in the rate o f infection from 16% to 4% with no deaths in the treated infants 
but a 25% mortality rate in infected babies in the control group. Gram negative 
organisms were isolated from all septic neonates and all septic episodes occurred 
during the first 76 hours o f life. These data suggested a protective effect o f IVIG 
against early onset bacterial sepsis with gram negative organisms.
Chirico et al.^^^^l administered a 500 mg/kg dose o f IVIG (Sandoglobulin) on 
the first day o f life, then weekly for a total o f four doses to 43 neonates with birth 
weight <1500 grams and gestational age of 24 to 34 weeks. 40 patients seiwed as 
control, in this randomised but not blinded study. Five per cent o f IVIG recipients 
developed sepsis and one o f the two infected babies died during the three month 
period o f obseiwation. In the placebo group 20% of neonates developed sepsis and 
75% of infected neonates died. Gram positive organisms were isolated in 60%. 
During the study period, IVIG was also administered to premature infants who 
weighed more than 1500 grams at birth. No protective effect o f IVIG was identified 
in these larger premature neonates.
Chirico's study was the first to suggest a protective role o f IVIG in the 
prevention of late onset nosocomial sepsis in VLBW infants.
Stabile et administered 500 mg/kg/day o f IVIG (Venogamma) on days 1
, 2 , 3 , 7 , 1 4 , 2 1  and 28 days o f life to 46 neonates weighing < 1500 grams or < 34
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weeks gestation. Forty eight (48) served as controls. Although the study was 
randomised and controlled, it was not blinded and the controls did not receive 
placebo. Proven sepsis was observed in 13% of IVIG recipients (thiee o f the five 
infected babies had meningitis) and in 8% o f the controls (one of three infected babies 
had meningitis). Infection occurred from 2 to 25 days o f age. Deaths occurred in 80% 
and in 33% o f IVIG recipient and control group with proved sepsis respectively. The 
organisms isolated from blood o f infected neonates included S. epidermides, S. 
aureus, Serratia, Klebsiella, Pseudomonas and Listeria, The results o f this study were 
unable to confirm any significant effect o f IVIG in the incidence o f sepsis in preterm 
infants. However the number o f subjects enrolled in this study may have been 
insufficient to detect a significant difference in the incidence o f sepsis between the two 
groups.
Bussel et al.^^^^l studied 126 neonates weighing < 1300 gram at birth. They 
were included in a randomised double blind controlled study. Sixty five received 
placebo and 61 received four doses o f 1000 mg/dose IVIG (Sandoglobulin) in the first 
5 days o f life and again on day 15. By 30 days o f life, 25% placebo recipients and 
15% o f IVIG recipients developed proven bacterial sepsis. By 70 days o f life, the 
incidence o f sepsis did not differ between the placebo and the IVIG recipients.
The results o f this study suggest that prophylactic IVIG may diminish the 
incidence o f nosocomial bacterial sepsis in VLBW neonates but the effect may not be 
sustained if the IVIG is administered only during the first few days o f life.
In a randomised, double blind, placebo-controlled study, Clapp et al.^ ^^ ®^  treated 
fifty six preterm infants with birth weight from 600 to less than 2000 grams with IVIG 
(Sandoglobulin) in the first 48 hours of life then every two weeks until discharge to 
maintain semm IgG at 700 mg/dl. Fifty nine neonates with the same birth weight
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aureus and 25% were due Candida.
affect the incidence o f deaths or necrotising enterocolitis.
received a placebo. Another 85 infants who were not enrolled in the study due to
.parent's refusal, were followed for incidence of infection. The initial dose of 500 
mg/kg o f IVIG was given to neonates weighing <1000 grams and 700 mg/kg to 
neonates weighing >1000 grams at birth. The subsequent doses o f IVIG (200 to 900 
mg/kg) were adjusted to maintain the semm IgG concentration above 700 mg/dl. ■>
IVIG recipients did not suffer from any septic episodes while 12% of placebo
treated babies and 10% of non randomised patients had at least one episode o f sepsis.
At the onset o f infection the semm IgG concentration was less than 400 mg/dl. The
incidence of infection between the three groups was significantly different. Thirty
.eight per cent (38%) of the septic episodes were due to S.epidermidis, 13% due to S. 3I 
S
.No infants with birth weight greater than 1300 grams developed infection 
therefore IVIG was not shown to reduce the incidence o f infection. IVIG did not
This finding suggest that when IVIG is administered repeatedly in doses 
sufficient to achieve a serum concentration > 700 mg/dl, it can reduce the incidence of 
nosocomially acquired sepsis in VLBW infants.
>'1-Baker et al.l^^^l in a multicentre, randomised, double blind placebo controlled 
study included 235 neonates with birth weight 500 to 1750 grams who received 
placebo and 229 who received 500 mg/kg IVIG (Gammagard) between days 3 and 5, 
after one week and then at 14 day intervals up to 5 doses. Proven bacterial sepsis 
occurred in 46% of babies in the placebo group and 34% o f IVIG recipients. The 
reason for the unusually high incidence o f bacterial sepsis in the control group was not 
clear. The administration o f IVIG was associated with diminished length o f
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hospitalisation and a reduction in the need for insertion o f central venous line. There 
was no difference in mortality rate between the two groups. The infusion o f IVIG did 
not affect the incidence o f sepsis in neonates weighing > 1500 grams at birth, the 
incidence o f necrotizing enterocolitis and the rate o f survival.
This large multicentre study suggests that repeated doses o f IVIG may reduce 
the incidence o f bacterial sepsis in VLBW infants.
Weisman et al.^ ^^ ^^  reported the result o f a multi centre, double blind and placebo 
controlled study designed to assess the efficacy o f a single dose o f IVIG administered 
prophylactically within the first 12 hours o f life to neonates weighing 500 to 2000 
grams at birth. Tlu'ee hundred and eighty one (381) neonates received placebo and 
372 received 500 mg/kg IVIG (Sandoglobulin).
The incidence o f bacterial sepsis, death and necrotizing enterocolitis was 
unaffected by the administration o f IVIG. This study suggests that, when IVIG is 
administered as a single dose on the first day o f life, it does not reduce the incidence
of nosocomial infection.
'
Conway et al.f*^^| administered 200 mg/kg o f IVIG (Intraglobulin) within 48 
hours of life then every 3 weeks during hospitalisation to 29 neonates with a 
gestational age less than 30 weeks. 26 neonates served as controls in this randomised 
but not placebo controlled study. Although the incidence o f apparent infection was 
reduced in the IVIG recipients, the incidence o f culture proven sepsis (8 o f the 29 
neonates) was not significantly different from that o f the controls (14 o f 26).
Therefore the results o f this study did not indicate that IVIG diminished the incidence 
o f bacterial sepsis of VLBW neonates.
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treated babies and were not significantly different. 15.5% of infected infants in the 
IVIG treated group and 14% of infected infants in the albumin treated group died 
from septic complications.
Magney et al.^^ '^ l^ in a randomised blind and placebo controlled study, 
administered 500 mg/kg o f IVIG (Biotransfusion) or albumin on days 0, 1, 2, 3, 17 
and 31 to 235 premature infants born at < 32 weeks gestation and less than 25 hours 
old with an endotracheal tube ± umbilical catheters on admission. They were observed 
for infection for 45 days. This dose was reported to maintain IgG  levels > 500 mg/dl 
for at least 45 days. They counted infection before the 5th day as maternal in origin. 
Nosocomial infection occurred in 38% of IVIG treated babies and in 31% albumin
Fanaroff (NICHD) study^^^^  ^ was a multi centre, prospective, randomised, 
controlled trial. They included infants with birth weights between 501 and 1500 
grams. Twelve hundred and four (1204) infants received IVIG, in a dose of 900 
mg/Kg to infants with birth weight 501 to 1000 grams and in a dose o f 700 mg/Kg to 
infants with birth weight between 1001 and 1500 grams within 72 hours o f birth then 
eveiy two weeks until they attained a weight o f 1800 grams or discharged from
hospital. Nosocomial infections were encountered in 17% and 16% of the IVIG and
1
■
i
I
■1
control group respectively. The result o f this study failed to demonstrated any 
reduction in the incidence o f nosocomial infection.
Summaiy: Many suggest that IVIG may be beneficial in
preventing neonatal infection. While other studies^^^ '^^^ '^^^^  ^ found no benefit for IVIG 
in prevention o f neonatal infection.
The cumulative data o f these reports suggest that IVIG in prophylactic use to 
prevent neonatal infection may not be effective in the current products or regimens.
%X-ÎÏ
■33;
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Chapter 2
2.1 Study population
During the period o f the study between September 1993 to August 1994 all 
infants born at Glasgow Royal Maternity Hospital with gestational age of 32 weeks or 
less, and weighing 1500 grams or less at birth, who needed intensive life support and 
whose parents consented to their participation, were included in the study. Intensive 
life support means those infants needing assisted ventilation, and those who had an 
umbilical catheter and or peripheral long lines for the first 2 days o f life. Infants who 
did not require intensive life support were excluded from the study on the basis of 
being clinically well.
From September 1993 to October 1994 ninety two (92) babies with birth 
weight <1500 grams and born at thirty two (32) weeks o f gestation or less, were 
admitted to the neonatal intensive care baby unit at Glasgow Royal Maternity 
Hospital. Tliirty eight (38) were included in the study.
Fifty four (54) infants who were not enrolled in the study were either;
1. Clinically well babies who did not need intensive life support.
2. Babies needing intensive care but whose parents refused to enrol them in the study.
Out o f a total o f 38 babies, nineteen (19) infants were randomised to the 
treatment group (IVIG) and nineteen (19) infants to the control group. Two babies 
from the control group died early and were excluded. Three babies from the treatment 
group died, two o f them died early (on day two and four) and were excluded from the 
study. The third infant died at the age o f thirty four (34) days. He received three IVIG
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group (88.3%). Steroid and thyroid releasing hormones were given to the mothers 
before premature deliveiy to enhance fetal lung maturation.
- 3
•Iinfusions, and died on the third day o f the third infusion. This baby was included for 
the 14 days period o f post infusion for two infusions but not after the 14 days post 
infusion period.
As can be seen in Table 2.1 there was no statistical difference in gestational age, 
birth weight, mode o f delivery, and Apgar score between the two groups. But there 
was a statistical difference in the administration of steroid to the mothers before
■delivery. Nine (9) out o f seventeen (17) mothers in the treatment group received 
steroid (52.9%) in comparison to fifteen (15) out o f seventeen (17) in the control
All the infants in the two groups developed respiratory distress syndrome and 
were ventilated. There was no significant difference in its severity, and ventilatoiy 
requirements among the two groups. However there was a significant difference in the 
incidence o f air leak (p <0.05 student's t test). Three (3) out o f seventeen (17) in the 
treatment group developed pneumothorax (17.6%) while none o f babies in the control 
group developed air leak. There was no statistical difference in the incidence o f patent 
ductus arteriosus and intraventricular/periventricular haemorrhage (p >0.05).
Medical management was dictated by the attending physician. Additional 
therapies include administration o f other blood products and pharmacological agents.
In the group o f babies receiving IVIG, 14 out o f 17 babies (82.3%) received at 
least one blood transfusion and 8 out o f 17 babies (47%) received FTP. In 
comparison, in the control group 15 out o f 17 babies (88.2%) received at least one 
blood transfusion and 10 out o f 17 babies (58.8%) received FFF. The mean numbers
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of transfusions was similar in the two groups. Two babies in the IVIG group (11%) 
received platelets and no patient in the control group received platelets. These results 
indicated no significant difference in blood and fresh frozen plasma (FTP) transfusion 
before the infusion and during the 14 days period post infusion between the IVIG 
group and control group. These babies received blood and FFP as part o f their 
intensive care management.
2.2 Methods
On admission all infants with gestational age o f less than 35 weeks were given 
500 micrograms o f vitamin K intramuscularly as a prophylaxis for a bleeding diathesis 
of the newborn. Also all infants with gestational age of less than 32 weeks were given 
vitamin E 25 mg intramuscularly daily for three days from birth then 30 mg orally as 
prophylaxis against retinopathy o f prematurity and intraventricular haemorrhage. 
Preterm babies with idiopathic respiratory distress syndrome needed intubation, 
assisted ventilation, umbilical arterial catheterisation and/or umbilical venous 
catheterisation and cover with antibiotics, Benzyl Penicillin and Netilmicin. This was 
the standard therapy used in the neonatal unit.
The parents were interviewed, the aim and the nature o f the study were fully 
explained and informed written consent obtained from the parent. The study protocol 
was approved by the Ethics Committee o f the Glasgow Royal Infirmary. As soon as 
parental consent was obtained, the baby was able to enter into the study. 
Randomisation was done by the hospital pharmacist and the baby was entered into 
one o f the study groups. One group received IVIG at a dose o f 500 mg/kg body 
weight to babies weighing 1001 to 1500 grams and 700 mg/kg body weight to babies 
weighing 1000 grams or less within 2 days o f birth. The other group (control) 
received an equivalent volume o f 5% dextrose on a double blind basis. These doses
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Table 2.1 Clinical data on treatment and control groups.
IVIG group (n = 17) Control group (n = 17)
SexM /F 11/6 11/6
Gestation age 27.7 ± 2.6 weeks 28 ± 2.23 weeks
Birth weight 1041 ± 2 5 7  grams 1065,9 ± 208 grams
Mode o f deliveiy
S.V.D.(%) 7/17 (41%) 5/17 (30%)
Forceps (%) ■— 1/17 (6%)
LUSCS 10/17 (59%) 11/17(65% )
Birth asphyxia 2/17(11.7% ) 1/17 (6%)
Apgar score at 5 min. 8.23 ± 2 .38 8.58 ± 1.90
FROM 4/17(23.5% ) 4/17 (24%)
Steroid to mother 9/17 (52.9%) 15/17 (88%)
Need o f surfactant (%) 12/17 (70.6%) 14/17 (82%)
Ventilation (%) 17/17 (100%) 17/17 (100%)
Duration o f ventilation 11.7 ± 14.7 days 10.3 ± 12
PDA 7/17 (41%) 4/17 (24%)
Air leak (%) 2/17 (17.6%) —
IVH/PVH (%) 7/17 (41%) 10/17 (59%)
Duration o f antibiotics 17.2±  11.6 14.3 ± 1.2
(days)
Umbilical A. catheter 13/17(76.5% ) 10/17 (59%)
(%)
Duration (days) 5.7 ± 2 ,6 5.5 ± 2 .6
Umbilical V. catheter 10/17(58.8% ) 9/17 (52%)
(%)
Duration (days) 3 .5 ±  1.5 3 .2 ±  1.5
Long line 12/17(70.5% ) 12/17 (71%)
Duration (days) 9.6 ± 4 .8 10.6 ± 6 .6
Days in I.T.U, 30.9 ±24.8 3 1 .2 ± 2 3 .7
Days in Hospital 59.8 ±36 .6 56.9 ±32 .5
Mean value ± S.D.
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were repeated at fortnightly intervals throughout the duration o f the baby's stay in 
intensive care and needed intensive care support.
5% dextrose was chosen on the basis o f it being similar in appearance and o f the 
same concentration o f sugar as IVIG. Thus the medical and the nursing staff did not 
know whether the baby received IVIG or 5% dextrose. The infusion materials were 
prepared by the pharmacist who also kept the randomisation codes, and were given to 
the doctor responsible for the study in a syringe so that the clinician supeiwising the 
infusion and those in charge o f the patients remained blind to the products received.
Thus double blind randomisation was maintained. The first infusion was given within 
the first two days o f life.
The doses o f IVIG (or placebo) were administered slowly using a syringe pump 
at an initial rate o f 0.6 ml/Kg/hour (0.5 pg/Kg/minute o f IVIG in IVIG group) for 30 
minutes. Then the dose was increased to 3.6 ml/Kg/hour (3 pg/Kg/minute of IVIG) 
provided there had been no adverse reaction to the infusion, such as change in heart 
rate, respiratory rate or blood pressure. These measures were recorded every 30
' f cminutes during the infusion period and one hour after.
■iBlood was taken from the infants before the infusion for the biochemical study
.(sodium, potassium, osmolality, sugar, urea, serum creatinine and serum bilimbin), full
blood count, blood gases and acid base balance (these were done routinely in the 
babies in the intensive care unit). 0.8 ml o f blood was also taken for IgG and 
opsonisation studies. Half way through the inftision, blood was also taken for blood 
gases and acid base balance. One hour after the infusion was completed, 0.8 ml o f 
blood was taken for IgG, biochemical study and blood gases and acid base balance. 
Urine was tested for protein and blood before the infusion and the day after. ,.,!4
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,'The next day, at 7 days and 14 days post-infusion, blood was taken for full 
blood count, and biochemical studies o f hepatic and renal function, so that acute and 
late onset side effects o f IVIG could be evaluated. Other blood samples (0.8 ml) were 
collected to check IgG levels and opsonic activity. The blood which was taken for 
IgG and opsonisation was centrifuged and the serum was taken. The semm for IgG 
was kept at -20 *^ C. Semm for opsonisation was heated in a water bath at 56 for 
30 minutes to remove the effect o f the complement, then kept at -20 till the tests 
were done. All sera from a single patient were tested for IgG on the same day.
Samples from a single patient were tested for opsonisation on the same day also so 
that the same source of neutrophils was used.
The patients were followed during the period o f hospital stay for evidence of 
infection such as deterioration o f their general condition, temperature instability, 
lethargy, vomiting, diarrhoea, abdominal distension, apnoea, tachypnoea, episodes of 
desaturation, hypotension, irritability, seizures, raised C-reactive protein, low platelet 
counts, high or low white blood cell counts or chest x- rays showing any evidence o f 
infection. All o f these signs and laboratory investigations were evaluated as possible 
signs o f sepsis even if the blood, cerebrospinal fluid or urine culture were negative. If 
the baby showed clinical deterioration as mentioned before and the blood, 
cerebrospinal fluid or urine culture were positive for any micro-organisms causing an 
infection, this was considered as being confirmatoiy evidence o f infection.
In addition to the above determinations, we measured the number o f days 
during which an antibiotic was administered to the infants after enrolment in the 
study, regardless o f the culture results. We also determined the number o f days during 
which an infant required assisted ventilation. The presence o f intracranial 
haemorrhage was determined using ultrasound evaluations for infants born at less than 
32 weeks gestation in the first day o f life and when clinically indicated.
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0.8 mi of blood was taken for full blood count and IgG at the age o f one, two 
and three months. If  the infant was discharged from the hospital before all the blood 
samples had been collected, arrangements were made for the baby to be reviewed as 
an outpatient when the blood samples were collected.
Serum immunoglobulin was measured by Immunonephelometiy assay in the 
Department o f Biochemistiy, Glasgow Royal Infinuary.
The study period o f three months was selected as more than 95% of the late- 
onset sepsis appeared to occur during the first two months and the lowest level o f IgG 
was reached by the age o f three to six months.
2.3 Material for Prophylaxis
Human immunoglobuiin for intravenous use
No target level of IVIG is known to prevent late onset bacterial sepsis in 
preterm babies and no known effective dose exists. In this study a dose o f 500 mg/kg 
for those with birth weight 1001-1500 grams and a dose o f 700 mg/kg to babies 
weighing less than 1000 grams was selected as previous studies suggested that these 
doses decreased bacterial infection. A iiigher dose o f IVIG might suppress immunity 
by decreasing bacterial clearance and survival in infected animals^^^^ ,^ decreasing adult 
monocyte^^^^^ and neonatal neutrophif phagocytosis o f bacteria in vitro. There are 
reports o f fatal infection in immuno-compromised adults after high doses o f IVIG
[124]
Immunoglobulin used in this study was prepared by the Scottish National Blood 
Transfusion Seiwice and consisted o f a lyophilised preparation o f IgG which was 
manufactured from unselected human plasma. It was prepared by conventional cold-
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ethanol fractionation followed by ultra-filtration and mild pepsin proteolysis at pH 4.
A wide range o f in vitro tests including opsonisation, neutralisation and antigen- 
specific complement binding have shown that antibody function is well preserved and 
that all IgG subclasses are present. The preparation has been shown to contain 
antibodies against a wide range o f viruses, bacteria and toxins.
Composition:
Each vial contains:
3 grams IgG.
6 grams sucrose.
N ot more than 300 pg porcine pepsin.
All constituents are present in a lyophilised powder form. After reconstitution, |
.the solution has a protein concentration o f approximately 45 grams/L and iapproximately 90 grams/L o f sucrose. More than 97% of the protein content is IgG.
yEach donated plasma used to manufacture the immunoglobulin preparation is carefully
■iscreened for any evidence o f Hepatitis B, Hepatitis C, Human Immuno-deficiency IVirus, or syphilis infections. The solution must be administered within four hours after ÏÏ
Sreconstitution.
2.4 Neutrophil Oxidation, Metabolism and Degranulation 
(Chemiluminescence [CL] ) :
Allen in 1972^ ^^^  ^ noted that after the addition o f particles or mico-organisms 
such as bacteria, yeast or zymosan to polymorphonuclear neutrophils, there was a
' Ifaint light emission. He subsequently showed that this phenomenon correlated well 
with other parameters o f oxidative metabolism and stimulation o f the hexose- 
monophosphate shunt. Light producing chemical reactions by a non-thermal process
I
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have been reported to occur after phagocytosis o f opsonised particles by human 
polymorphonuclear neutrophils, eosinophils and monocytes. Such CL appears to be 
related to the generation o f intermediate products o f oxygen reduction such as singlet 
oxygen, super oxide and hydroxyl radicals which have been implicated as microbicidal 
agents.
a
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In this phenomena (CL) the light is produced by a chemical reaction, the 
molecule responsible for emitting the light, absorbs free energy released by the 
reaction and becomes excited. In this state some of the peripheral electrons o f the 
molecule are raised to a higher energy level. When these electrons lose energy they 
return to a lower energy level and the energy lost during this transition is emitted as 
photons, i.e. light. When the electrons have lost all their absorbed energy the molecule 
is then back in Its stable state. The colour and wave length o f the emitted light depend 
on several factors, including the type of molecule excited, the pH of the liquid 
medium, the presence o f metal ions, the type of catalyst and the amount o f free energy 
released by the chemical reaction.
The amount o f light in CL is increased by the addition o f soluble protein, such 
as the amino acids tyrosine and tryptophan, to the reaction medium. These agents
appear to produce their effects not by increasing the rate of phagocytosis but by 
providing a substrate for secondary light-producing reactions which occur outside of I
the phagocyte. - -'k:I
The intensity o f light emitted depends on the reaction rate o f the oxido- 
reduction step which in turn depends on the concentration o f molecules taking part in 
the reaction. Light intensity is therefore directly proportional to the concentration of 
the reactants. In practice only key substances such as adenosine triphosphate (ATP), 
nicotinamide adenine dinucleotide phosphate {ADN(P)H) and hydrogen peroxide
«
(H2 O2 ) are measured directly by light measurement. CL has been used as a technique 
to investigate the de-granulation of polymorphonuclear neutrophils and their cytotoxic 
ability and it has become widely used as a replacement or alternative method for many 
assays carried out, such as catorimetry, spectrophotometry and the counting of 
radioactive emissions.
Advantages of CL
1. Higher sensitivity.
2. Wide measurement range.
3. Smaller specimens.
4. Safe to use, simple, lower cost instrumentation.
5. Highly specific, stable, non toxic reagent used providing rapid measurement.
Oxidative metabolism o f other phagocytic cells can also be evaluated by the 
chemiluminescence method. Monocytes emit light intensity in approximately one third 
o f that o f neutrophils, and eosinophils emitting light with intensity equal to that of 
neutrophils. Luminescence analysis is based primarily on three light producing 
systems:
1. Firefly bioluminescence for the measurement o f ATP.
2. Bacterial bioluminescence for the measurement o f NAD(P)H.
3. Luminol chemiluminescence for the measurement o f H 2 O2 .
Luminol chemiluminescence
Luminol (5 amino 2,3 dihydro 1,4 phthalazenedine) is a synthetic compound 
which emits light when oxidized by either peroxides or oxygen radicals. It interacts 
with these oxidising species to produce larger, more measurable amounts o f light at a 
peak wave length o f approximately 425 nm. The reaction proceeds much faster in the
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presence o f certain metal ions and metal containing complexes such as haematin, the 
active group in haemoglobin.
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Chemiluminescence assay
The PICO-LITE Model 6500 Luminometer system was used in our 
Chemiluminescence study. The PICO-LITE is an analytical instrument used to
■■
measure light (protons) emitted by biological and chemical reactions (bioluminescence 
and chemiluminescence). The PICO-LITE consists of a Detector and an Analyser 
which includes a printer.
I
The temperature was set at 37 °C at least 30 minutes before the mn, and the
computer was programmed as per protocol up to a starting point. 100 ul o f opsonised
E. coli or GBS and 50 ul o f 10"  ^ M luminol were added to each vial which were
placed in the darkened chambers o f the luminometer (Packed Picolite-Model number
5600) which was kept at a temperature o f 37 °C. Then 100 ul o f PMN were added to
.each vial. A ratio of 50:1 of bacteria to PMN was found to give the optimum CL 
response. The CL was measured and was quantitated by the peak high o f the 
response.
a. Isolation of polymorphonuclear cells from peripheral blood
Polymorphonuclear (PMN) cells were prepared from peripheral blood (blood
samples were taken from healthy adult volunteers) using a modification o f the method
described by Boyum (1968). 7 ml of heparinised blood is added to  3 ml o f 5%
solution o f Dextran in saline. After 30 minutes the PMNs rich plasma is layered gently
into an equal volume of polymorphonuclear separating fluid (13.8% sodium
.metrizoate, 8% Dextran). The PMN layer is transferred into a tube in which PMNs 
are washed in Gel Hanks solution containing 0.1% gelatine. This is centrifuged at
I
1400 rpm for 5 ininutes. The PMN cells are resuspended in Gel-Hanks solution at a 
concentration o f 1x10^ ml‘^
b. Preparation of bacteria
The bacterial preparation is used for the measurement o f the killing ability of 
PMNs on opsonised bacteria with serum from the patient. 10 ml o f Mueller- Hinton 
was inoculated with type III group B streptococci or E. coli (k l). These organisms 
were isolated from sick new-born babies who had died from septicaemia. The broths 
were incubated overnight at 37 °C. The bacteria were washed 3 times in sterile saline. 
The concentration o f organisms was adjusted to 5x10^ colony forming units 
(CFU)/ml, using a Cecil spectrophotometer. An optical density of 0.45 at 620 nm 
corresponded to 5xlO^CFU/ml.
5x10^ CFU quantity o f bacteria (E. coli and group B streptococci ) were 
preopsonised separately by incubation in 1 ml (equal volume) o f 10% o f the patient's 
serum diluted in Gel-Hanks (buffer) solution at 37 °C for 15 minutes in an orbital 
shaker. Optimum opsonisation o f GBS and E. coli was found to be in 10% of human 
semm. There was no significant difference in opsonisation between 10% and 20% 
human semm.
The serum was collected from the 0.4 ml o f blood which was taken from the 
neonate before the infusion o f IVIG or 5% dextrose, 24 hours, 7 days and 14 days 
after each infusion. The semm was heated at 56 °C for 30 minutes to remove the 
effect o f complement. All samples from each baby were done on the same day, so that 
the PMNs used were from the same donor. Therefore any difference in the CL results 
was due to the effects of the IgG in the semm of the different samples. After I
incubation for 15 minutes the opsonised bacteria were centrifuged at 3000 rpm for 15
1
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minutes and the supernatant was discarded. The organisms were resuspended in the 
original volume o f Gel-Hanks.
Statistics
Comparability o f the demographic data o f the IVIG treated and control group 
were assessed using the student's t test. Infection rates among the two study groups 
were compared by the chi-square test. All data were expressed as mean ± standard 
deviation. A p value o f < 0.05 was considered significant.
' f
i
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Chapter 3 
Results
As noted from Table 2.1 there was no significant difference in the sex, 
gestational age, mode o f delivery, Apgar score, duration o f ventilation and use of 
surfactant between the IVIG and control group. There was no significant difference in 
the duration o f antibiotic therapy between the two groups. The infants receiving IVIG 
were hospitalised for a mean period o f 59.8 ± 36.6 days wliich was not significantly 
different from 56.9 ± 32.5 days in the control group. Also there was no significant 
difference in the total number o f days during which infants required intensive care 
support. The mean period of intensive life support was 30.3 ± 24.8 days for IVIG 
recipients and 31.2 ± 23.7 in the control group.
Two babies in the control group died early in the study period and were 
excluded from the trial. Two babies in the IVIG group also died early in the study 
period and were excluded from the trial. Another one died at 32 days o f age. He was 
included in the study until 14 days after the last IVIG infusion,
Number of deaths in the control group (Table 3, 1)
Case 1: Delivered at 26 weeks, had grade III IVH from day one, severe 
idiopathic respiratoiy distress syndrome and persistent pulmonaiy hypertension. On 
the second day he developed pulmonary haemorrhage. Despite continuing maximum 
life support, the baby died on day two.
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Case 2: The second infant delivered at 24 weeks, had severe RDS, IVH grade 
IV from the first day, and a coagulopathy. PDA was treated with indomethacin. He 
had progressive ventricular dilatation and ventilatoiy support was withdrawn on day 
12 when he was declared brain dead.
Both patient blood cultures were negative.
Number of deaths in the IVIG group (Table 3. 2)
Case 1: Preterm baby delivered by caesarean section at 26 weeks, had severe 
hypotension since birth leading to pre-renal failure, severe RDS complicated by 
recurrent pneumothoraces wliich ultimately led to respiratory failure and death at the
improvement in respiratory disease, had grade IV IVH/PVH from day 2 which led to 
convulsions and brain death. Respiratory support was withdrawn at the age of 34 days 
when the baby died.
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age o f 9 days. Blood culture at 8th day was positive for Staphylococcus epidermidis.
Case 2: Premature baby delivered at 26 weeks, had severe RDS which led to 
.recurrent bilateral pneumothoraces treated by the insertion of a chest drain. The baby 
was also hypotensive and was found to have significant coagulopathy. Despite 
maximum support, the baby died from severe hypoxaemia at the age o f 4 days. Blood 
cultures were negative.
Case 3: Premature baby delivered at 25 weeks who, despite steady and marked
Table 3.1 Clinical details o f dead infants in IVIG group
Case
No.
Sex Mode o f  
delivery
Biitlr
weight
(grams)
Ges.
Age
(weeks)
Apgar 
score at 
5 mill
Severity 
o f  RDS.
Ventilation
(days)
IVH/P
VH
Age
at
death
(days)
Cause 
o f death
Other
1 M LUSCS 980 26 10 Sev. 9 - 9 RDS+ Fn.+ Hyp.+
Pn. PDA
2 F LUSCS 630 26 10 Sev. 4 - 4 RDS. + Pn. + Hyp. 1
Pn. P.H.+ ;•
Coagulopath
-
y
3 M LUSCS 730 26 5 Mod. 38 Grade 34 Brain PDA +IVH +
IV death Con.
Table 3.2 Clinical details o f dead infants in the control group
Case
No.
Sex Mode o f  
deliveiy
Birth
weiglit
(grams)
Ges.
Age
(weeks)
Apgar 
score at 
5 mill
Severity 
o f  RDS.
Ventilation
(days)
IVH/P
VH
Age at 
death
Cause 
o f death
Other
1 M LUSCS 1250 26 6 Sev. 2 Days - 2 RDS+
P.P.H.
Hyp.+ P.H.
2 F S.V.D. 800 24 8 Mod. 12 Days Grade
IV
12 RDS.
Brain
deatli.
PDA + 
Coagulopatli
y
;
I
ÎI
PDA = Patent ductus arteriosus, 
Pn. = Pneumothorax.
Hyp. = Hypotension.
P.P.H. = Persistent pulmonary hypertension. 
P.H. = Pulmonary haemorrhage.
Con.= Convulsion.
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3.1 Incidence of late onset sepsis
immature to total neutrophil ratio o f greater than 0.2, leucocytosis, chest x ray shows 
evidence o f infection, high c- reactive protein and low platelets count.
Suspected episodes o f sepsis were defined as clinical symptoms and signs 
suggesting sepsis or any investigation including chest X-ray showing a signs of 
infection but no micro-organisms isolated from blood, cerebrospinal fluid, or urine on 
culture.
In this study the infLision o f IVIG was given eveiy 14 days, due to the fact that 
exogenous intact gammaglobulin is rapidly catabolised by the neonates, with a half life 
o f about 11-14 days (4 to 7 days for specific antibody), compared with an average 
half life o f 3 weeks in adults. Among neonates with birth weight less than 1000 grams, 
doses as high as 900 mg/Kg eveiy 2 weeks did not sustain a target level o f 700 mg/dl 
o f serum IgG for 14 days in 60% of infusions. Even among infants weighing more 
than 1000 grams, it was difficult to sustain semm levels for two weeks with doses of 
500 to 900 mg/Kg o f IVIG^^^'^l High doses o f IVIG might suppress immunity by 
decreasing bacterial clearance. These studies indicated that the serum level was not 
maintained above the target level after 14 days o f IVIG infusion.
Î
iLate onset sepsis was defined as sepsis occurring at or after the age o f five (5)
.days. Proven sepsis was defined as clinical symptoms and signs consistent with sepsis 
in association with isolation o f a significant organism from a blood culture specimen, 
cerebrospinal fluid or bladder stab urine. Clinical signs consistent with sepsis were 
respiratory distress in the form o f apnoea, tachyponea, increased oxygen requirement
'or a severe form requiring mechanical ventilation, hypotension, acidosis, temperature 
instability, lethargy, vomiting, diarrhoea, poor feeding abdominal distension, ileus, 
seizures, petechiae or purpuric rash and in a laboratoiy form as neutropenia, an
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Therefore the infused IVIG did not have a major role in the protection of 
preterm babies against bacterial infection after 14 days. In our study we divided the 
period during which infection could occur into two:
1. Within 14 days post infusion.
2. After 14 days post infusion.
Therefore any difference in the incidence o f infection after 14 days post infusion 
period was due to chance rather than to the effect o f the infused immunoglobulin.
a. Incidence of proven sepsis within the fourteen days post infusion 
period
Five (5) out o f seventeen babies (17) in the IVIG group (29.4%) developed 
episodes o f proven sepsis within 14 days post infusion period (Table 3,3) in 
comparison to nine (9) out of seventeen (17) babies (52.9%) in the control group.
(X  ^= 1.96, 0.05 > p > 0.01).
These results indicate that there is no statistical significant difference in the 
incidence o f proven sepsis within 14 days post infusion between the IVIG group and 
the control group (Figure 3.1). Although, there was an overall reduction in sepsis in 
the IVIG group in comparison to the control group, these results are not statistically 
significant. The apparent reduction in the incidence o f sepsis in IVIG group was noted 
mainly in babies with birth weight o f < 1000 grams. (Table 3.4).
In the group o f babies (Figure 3.2) with birth weight <1000 grams, four (4) out 
o f seven babies (7) in the IVIG group (57.1%) developed episodes o f proven sepsis in 
comparison to seven (7) out o f eight (8) babies (87.5%) in the control group.
(X ^= 1.75, 0.25 > p >  0.10).
74
Although the IVIG group shows a decrease in the incidence o f proven sepsis in 
comparison to the control group, this is not statistically significant.
shows that 7 episodes o f proven sepsis occurred in 4 infected babies in the IVIG 
group in comparison to 13 episodes in 7 infected babies in the control group
There were two episodes o f proven sepsis in one infected baby in the IVIG 
group in comparison to two episodes in two infected babies (one episode each ) in the 
control group [p > 0.05].
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Analysis o f the number o f episodes in babies with birth weight < 1000 grams ;
(p > 0.05). There was no significant difference between the IVIG group and the 
control group in relation to the number o f episodes.
There were no episodes o f proven sepsis in babies with birth weight o f 1001-
1250 grams in either group. In the group of babies with birth weight 1251-1500 
grams, one (1) baby out o f four (4) in the IVIG group had episodes o f proven sepsis 
as compared to two (2) out five (5) babies in the control group.
(%^  =  0.223, 0.75 > p >  0.50). I
These results indicate that there is no statistical significant difference in the
:incidence of proven sepsis or in the number of the episodes in this age group between
....
IVIG and control groups.
In the whole group o f babies with birth weight < 1500 grams, five (5) out of
seventeen (17) babies (29.4%) in IVIG group had a total o f nine (9) episodes of
. . .proven sepsis within 14 days post infusion period in comparison to nine (9) out of 
seventeen (17) babies (52.9%) in the control group who developed 15 episodes 
[p > 0.05]. These results indicate that there is no statistically significant difference in
the number of episodes o f proven sepsis between the IVIG group and the control in 
spite o f an apparent overall difference. The episodes o f proven sepsis occurred mainly 
after the age o f five days in the control group.
Analysis o f the causative micro-organisms (Table 3.5) in the IVIG group shows 
that babies with birth weight <1000 grams had seven (7) episodes o f sepsis and all of 
them were due to Staphylococcus epidermidis, while only one baby with birth weight 
o f 1251-1500 grams had two episodes of proven sepsis, one due to Candida 
septicaemia and the second one due to Enterobacter.
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In the control group, 12 episodes out o f 13 (92.3%) in babies with birth weight
< 1000 grams were due to Staphylococcus epidermidis and one out o f 13 (7.6%) was 
due to Candida albicans. The two episodes in babies with birth weight of 1251-1500 
grams were also caused by Staphylococcus epidermidis.
b. Incidence of proven sepsis after 14 days post infusion period
In the IVIG group five (5) out o f sixteen (16) babies (31.2%) developed 
episodes o f proven sepsis in comparison to three (3) out o f seventeen (17) babies 
(17.6%)) in the control group ( Table 3.3).
( X ^  = 0.82, 0.50 > p  >0.25 ).
These results indicate that there was no statistically significant difference 
in the incidence of proven sepsis after 14 days between the IVIG and control groups 
(Figure 3.2).
Table 3.3 Incidence o f proven sepsis in IVIG and control groups.
Time o f proven sepsis IVIG group Control group
Within 14 days 
After 14 days
5/17(29.4% ) 
5/16 (31.2%)
9/17(52.9% )
3/17(17.6% )
Table 3.4 Incidence o f proven sepsis within 14 days post-inflision at different birth 
weights in IVIG and control groups.
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Birth weight IVIG group Control group
<1000 grams 
1000 - 1250 grams 
1251 “ 1500 grams
4/7 (57.1%) 
0/6 
1/4 (25%)
7/8 (87.5%) 
0/4 
2/5 (40%)
I
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20
10
0
Within 14 days After 14 days 
Time of proven sepsis 
Figure 3.1 Incidence o f proven sepsis in the IVIG and control groups
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Figure 3.2 Incidence o f proven sepsis within 14 days in the IVIG group at different 
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The analysis o f the incidence o f proven sepsis after 14 days post infusion in 
different birth weight groups indicates that there is no significant difference between 
the two groups. One (1) out o f eight (8) babies (12.5%) in the control group with 
birth weight < 1000 grams in comparison to three out of six (50%) in IVIG group had 
episodes o f proven sepsis (Table 3.6)
(%^=2.36, 0.25 > p  >0.10).
One (1) out o f four (4) babies (25%) in the control group with birth weight 
1001-1250 grams had an episode o f sepsis in comparison to two (2) out of six (6) 
babies (33.3%) in the IVIG group.
(X  ^= 0.075, 0.90 > p > 0 .7 5 ).
In the group o f babies with birth weight o f 1251-1500 grams, no babies in the 
IVIG group had episodes o f proven sepsis while one (1) out of five (5) babies in the 
control group (20%) had an episode o f proven sepsis after 14 days post infusion.
(x^ = 0.897, 0.50 > p > 0.25).
These results indicate that there is no significant difference in proven sepsis 
between babies of different birth weight in the IVIG and control groups.
Five (5) episodes o f proven sepsis occurred in the five infected babies in the 
IVIG group in comparison to six (6) episodes in three infected babies in the control 
group (p > 0.05). That means there is no significant difference in the number o f the 
episodes between the two groups.
All o f the episodes in the control group were due to Staphylococcus epidermidis 
and occurred at the age o f 17 to 50 days.
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In the IVIG group four 4 out o f 6 episodes were due to Staphylococcus
.epidermidis and one was due to Enterococcus (streptococcus) faecalis.
In the IVIG group the episodes o f proven sepsis occurred between the age o f 
twenty (20) days and seventy six (76) days. Three babies had four (4) episodes of 
Staphylococcus epidermidis septicaemia. One baby had Enterococcus faecalis 
septicaemia at age o f 74 days. Table 3.5 shows the causative micro-organisms in both 
groups up to three months of age.
Twenty one episodes o f proven sepsis occurred in babies in the control group 
within this three month period, twenty o f which were due to S. epidermidis and one 
due to C. albicans. Fourteen out o f these 21 episodes (66.6%) were associated with 
the presence o f a long line. Fourteen episodes o f proven sepsis occurred in the IVIG 
group, eleven out o f these fourteen were due to S. epidermidis and six (42.8%) 
associated with the presence o f a long line. Therefore 57.1% o f infection episodes 
were associated with the presence o f a long line.
Twelve out o f 35 episodes (34.2%) o f proven sepsis were accompanied by 
raised C- reactive protein. Two episodes were due to Candida albicans and 10 
episodes were due to S. epidermidis. In the remaining 23 episodes C- reactive protein 
was not raised. C- reactive protein was raised to a high level (it reached 125 mg/dl in 
one case) in infection due to C. albicans, while in infection with S. epidermidis the C- 
reactive protein usually raised to a lower level but only in two cases it was raised to
I81 and to 86 mg/1.
It is noted that most of the infants in this study did not develop infections with 
organisms widely recognised as pathogens in neonates, such as GBS and enteric 
gram negative organisms. Rather, the infecting micro-flora represented organisms
i
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Table 3.5 Causative micro-organisms in IVIG and control groups within a 3 month 
period.
Micro-organisms IVIG group Control group Total 
(IVIG + control)
S. Epidermidis 78.6% 95.2% 88.5%
Candida albicans 7.1% 4.8% 5.7%
Enterobacter 7.1% — 2.9%
Enterococcus
faecalis
7.1% — 2.9%
Table 3.6 Incidence o f proven sepsis after 14 days post-infusion at different birth 
weights in IVIG and control groups.
Birth weight IVIG group Control group
<1000 grams 
1001 -1250 grams 
1251 - 1500 grams
3/6 (50%) 
2/6 (33.3%)
0/4
1/8 (12.5%) 
1/4 (25%)
1/5 (20%)
■
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commonly encountered in nosocomial infection in other inpatient intensive care 
population. The commonest was S. epidermidis.
c. Incidence of suspected sepsis within fourteen (14) day post infusion 
period
The definition o f suspected sepsis means that the baby was unwell, had signs 
suggestive of sepsis and antibiotics were given but cultures of blood, cerebrospinal 
fluids or urine were negative.
In the IVIG group ten (10) out o f seventeen (17) babies (58.8%) developed 
episodes o f suspected sepsis within the 14 day post-infLision period (Figure 3.4) in 
comparison to eleven (11) out o f seventeen (17) babies (64.7%) in the control group 
(Table 3.7).
(X^  = 0.122, 0.75 > p >  0.50).
These results indicate that there is no significant difference in the incidence of 
suspected sepsis within 14 days post-infusion between the IVIG and control group. 
But there is a significant difference in the number o f the episodes of suspected sepsis 
between the two groups (p < 0.05). In the control group 26 episodes o f suspected 
sepsis occurred in comparison to 13 episodes in IVIG group.
In the IVIG group (Table 3.8) six (6) out of seven (7) babies (85.7%) with 
birth weight <1000 grams in comparison to eight (8) out of eight (8) babies (100%) 
in the control group had episodes of suspected sepsis within 14 days post infusion 
(Figure 3.4), (x^ = 1.209, 0.25 > p > 0.10).
■t
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Babies in the control group had 23 episodes in comparison to 9 episodes in 
IVIG group (p < 0.05) , which is statistically significant. I
Two out o f six babies (33.3%) with birth weight 1001-1250 grams in the IVIG 
group had episodes o f suspected sepsis (two episodes) in comparison to none in the 
control group. That means there is no significant difference between the two groups. 
(x^= 1.666, 0.25 > p > 0 .1 0 ) .
In the control group three out o f five babies (60%) with birth weight 1251-1500 
grams in comparison to two out of four babies (50%) in IVIG group had an episode
o f suspected sepsis. There is no significant difference between the two groups. 
(X^= 0.086, 0.90 > p >  0.75).
■in
In this age group, babies in the IVIG group had 3 episodes in comparison to 4 
episodes o f suspected sepsis in control group (p > 0.05). That means no significant 
difference between the two groups.
d. Incidence of suspected sepsis after the 14 day post infusion period
Seven out o f 16 babies (43.7%) in the IVIG group had episodes o f suspected 
sepsis (Table 3.7) in comparison to two out o f 17 babies (11.7%) in the control group 
after the 14 days post infusion period (Figure 3.4), (x = 4.25, p < 0.05).
IThese results indicate that there is a statistically significant difference between 
the two groups against the IVIG group as more babies in this group had episodes of 
suspected sepsis. Table 3.9 shows the incidence o f suspected sepsis after the 14 days 
post-infusion period at different birth weights in both groups (Figure 3.6).
i
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Table 3.7 Incidence o f suspected sepsis in the IVIG and control group.
Time o f suspected sepsis IVIG group Control group
Within 14 days 
After 14 days
10/17(58.8%)
7/16(43.7% )
11/17(64.7% )
2/17(11.7% )
Table 3.8 Incidence o f suspected sepsis within 14 days post-inlusion in the IVIG and 
control groups matched by birth weight group.
Birth weight IVIG group Control group
<1000 grams 
1001 -1250 grams 
1251 -1500 grams
6/7 (85.7%) 
2/6 (33.3%) 
2/4 (50%)
8/8 (100%) 
0/4 
3/5 (60%)
Table 3.9 Incidence of suspected sepsis after 14 days post infusion at different birth 
weights in the IVIG and control groups.
Birth weight IVIG group Control group
< 1000 grams 
1001 -1250 grams 
1251 -1500 grams
2/6 (33.3%) 
4/6 (66.6%) 
1/4 (25%)
0/8 
0/4 
2/5 (40%)
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Figure 3.5 Incidence of suspected sepsis within 14 days post infusion in the IVIG and 
control groups at different birth weights
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Figure 3.6 Incidence o f suspected sepsis after 14 days post infusion in the IVIG 
group at different birth weight
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There is no statistically significant difference in the number o f the episodes 
between the two groups. Seven babies had eleven episodes in the IVIG group in 
comparison to three episodes in two babies in the control group ( p > 0.05).
There was no significant difference (Table 3.10) in the number o f babies fed 
breast milk, formula milk or a mixture of the two between the IVIG and control 
groups. Also there was no significant difference in the incidence o f proven septic 
episodes and suspected necrotising enterocolitis between babies fed breast milk, 
formula milk or a mixture of the two in both study groups (Table 3.11).
Three babies in the IVIG group developed signs of suspected necrotising 
enterocolitis. One was fed breast milk, one formula milk, and the third fed a mixture 
of the two. Two babies in the control group developed signs o f suspected necrotising 
enterocolitis, one was fed breast milk and the second fed formula milk.
As noted from these results, breast milk in our study did not seem to make any 
difference to the incidence o f infection episodes or suspected necrotizing enterocolitis.
88
Table 3.10 Type o f feeding in the IVIG and control groups
Type o f feeding IVIG group Control group
Breast feeding 3/17 1/17
Formula feeding 6/17 8/17
Mixed feeding 8/17 8/17
Table 3.11 Incidence of infection in relation to the type of feeding
Feeding/infection IVIG group Control group
Breast feeding 1/3 1/1
Formula feeding 2/6 4/8
Mixed feeding 2/8 4/8
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3.2 Effect of intravenous immunoglobulin on serum IgG level
At the study entiy the mean serum concentration o f IgG in the IVIG group was 
456 ± 162 mg/dl (range: 240 - 770 mg/dl) and 467 ± 37 mg/dl (range: 310 ~ 740 
mg/dl) in the control group. These results indicate that there was no significant 
difference in the mean serum IgG concentration at the enti'y of the study, p > 0.05 
(Figure 3.12). After the first infusion the mean concentration o f IgG was significantly 
increased in the IVIG group throughout the first 14 days (p < 0.001). There was no 
significant change in the control group IgG concentration one hour after the initial 
infusion whereas the mean serum IgG concentration in IVIG group increased by 
230% from the pre-infusion level.
Although the mean serum IgG concentration had decreased to 72 % of the peak 
post-infusion level by 24 hours in IVIG group, it still remained 166 % above the 
baseline. At 7 days the mean semm IgG concentration in the IVIG group was 149.3% 
above baseline (decreased to 65 % o f the peak post-infusion level) and at 14 days it 
was 121.7 % above baseline (decreased to 53% of the peak post infusion in the IVIG 
group).
By the end of the second week, five (5) babies in IVIG group still needed 
intensive life support as did another 5 babies in the control group. These babies 
received a second infusion.
The mean seium IgG pre-infiision level (Table 3.13) was 574 ± 216 mg/dl 
(range: 320-880 mg/dl) in the IVIG group in comparison to 422 ± 89 mg/dl 
(range: 350-550 mg/dl) in the control group. These results indicate that there was no 
significant difference in the mean IgG concentration between the two groups, p > 0.05 
(Figure 3.8).
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By 24 hours post-infusion, the mean serum IgG concentration in the IVIG 
group had decreased to 81% o f the peak post-infusion level, but this is still above the 
baseline by 171 %. At the 7th day the mean serum IgG concentration in the IVIG 
group was 116.7 % above the baseline (55% of the peak post-infusion level) and by 
14 days it was 102.7 % above the baseline level (49% of the peak post-infusion level).
By the age o f one month two babies in each group were still receiving intensive 
life support, and a third dose was given to them.
significantly increased in the IVIG group throughout the 14 days period post-infusion, 
p < 0.001 (Figure 3.9).
Throughout the first 14 days after the second infusion, the mean serum IgG 
concentration in the IVIG group was significantly increased in comparison to the 
changes in the mean serum IgG concentration in the control group (p < 0.001).
There was no significant change in the mean seaim IgG concentration in the 
control group one hour after the infusion whereas the mean serum IgG concentration Î
in the IVIG group increased by 210 % from the pre-infusion level.
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After the third infusion (Table 3.14) the mean serum IgG concentration was Î
There was no significant change in the control group IgG concentration one 
hour after the infusion, whereas the mean serum IgG concentration in the IVIG group 
increased by 220% from the pre-infusion level.
Although the mean semm IgG concentration had decreased to 79 % o f the peak 
post-inflision level by 24 hours in the IVIG group, it still remained 175.8 % above the 
baseline.
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At day 7 the mean serum IgG in the IVIG group was 141.3 % above the 
baseline (63% o f the peak post infusion level) and at 14 days it was 125.5 % above 
the baseline (56% of the peak post-inHision level).
I
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One baby in the IVIG group, a second twin delivered at 28 weeks o f gestation, 
was ventilated for 55 days. She needed a 4th infusion o f IVIG at the age o f 46 days. 
No baby in the control group needed a fourth infusion.
The pre-infusion IgG concentration (Table 3.15) was 580 mg/dl. This increased
by 190% one hour after the infusion. After 24 hours the mean serum IgG 
.concentration decreased to 76% of the peak post infusion level, but it still remained 
144.8 % above the baseline. By 7 days the mean serum IgG concentration decreased 
further to 74% of the peak post infusion level, although it still remained 141.4 % 
above the baseline. At 14 days the mean was 129.3 % above the baseline (68% o f the
,.;;s
peak post-infusion level) {Figure 3.10}.
There was a significant difference between the two groups (Table 3.16) in the 
mean concentration o f IgG during the first and the second months o f life, but there 
was no significant difference at the age o f three months.
At the age o f one month the mean serum IgG concentration in the IVIG group
was 413 ± 1 6 7  mg/dl (range; 280-670 mg/dl) in comparison to 273 ± 63 mg/dl (range:
170-370 mg/dl) in the control group (p < 0.05). These results indicate a statistically 
.significant difference between the IVIG group and control group in the mean IgG Iconcentration at the age o f one month.
::I
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At the end o f the second month of life, the mean IgG concentration in the IVIG 
group was 331 ± 183 mg/dl (range: 160-760) in comparison to 152 ± 49 mg/dl 
(range: 100-230) in the control group (p < 0.05).
That means there is a significant difference in the mean IgG concentration 
between the control and IVIG groups.
The mean concentration o f IgG in the IVIG group was slightly higher than that 
in the control group at the age o f three months. It was 218 ± 90 mg/dl (range: 100- 
670 mg/dl) in comparison to 113 + 3 2  mg/dl (range: 60-160 mg/dl) in the control 
group (p > 0.05). This was not statistically significant, ( Table 3.16).
Table 3.17 and Table 3.18 shows the mean concentration o f IgG in the control 
group and IVIG group at the age o f 1 ,2  and 3 months in babies o f different birth 
weights.
The mean IgG concentration at the age o f one month (Table 3.19) in those 
babies who received only one dose o f IVIG was 338 ± 102 mg/dl (range: 100 - 470 
mg/dl) in comparison to 262 ± 63 mg/dl (range: 170 - 340 mg/dl) in the control group 
(in the group of babies who were chosen from the whole group with matched 
gestational age), p> 0.05.
At the age o f two months the mean semm IgG concentration in the IVIG group 
was 241 ± 71 mg/dl (range: 160-380 mg/dl) in comparison to 153 ± 57 mg/dl (range: 
100-230 mg/dl) in the control group (p < 0.05).
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Table 3.12 Effect o f IVIG on serum concentration of IgG (before and after the first
infusion).
Time IgG Concentration (mg/dl)
Control group IVIG group
Before infusion 467+  137 456 + 162
1 hour after infusion 492+  141 1045 + 253 *
24 hours after infusion 508 + 146 757 + 201 *
7 days after infusion 484+  119 681 + 140
14 days after infusion 402+  120 555 + 148 *
n = 17 (control group), 
n = 17 (IVIG group).
* = significant.
Table 3.13 Effect o f IVIG on serum concentration o f IgG (before and after the 
second infusion).
Time IgG Concentration (mg/dl)
Control group IVIG group
Before infusion 
1 hour after inftision 
24 hours after infusion 
7 days after infusion 
14 days after infusion
4 2 2 +  89 
4 1 2 +  71 
404+  89 
368 + 79 
284+  57
574 + 216 
1208 + 276 * 
982 + 221* 
670+  122* 
590+  146*
n = 5 (control group), 
n = 5 (IVIG group).
* = significant.
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Figure 3.7 Serum IgG concentration in the IVIG and control group before and after 
the first infusion 
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Figure 3.8 Semm IgG concentration in the IVIG and control group before and after 
the second infusion 
m (control) = 5 
m (IVIG) = 5
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Table 3.14 Effect o f IVIG on serum concentration o f IgG (before and after the third
infusion).
Time IgG Concentration (mg/dl)
Control group IVIG group
Before infusion 
1 hour after infusion 
24 hours after infusion 
7 days after infusion 
14 days after infusion
285 ± 07 
300 ± 00 
380 ± 5 6  
295 ± 07 
280 ± 28
506 ± 120* 
1120± 173* 
8 9 0 ± 160* 
715 ±205* 
635 ±77*
n = 2 (control group), 
n = 2 (IVIG group).
 ^ = significant.
Table 3.15 Effect o f IVIG on semm concentration o f IgG before and after the fourth 
infusion (no one in the 5% dextrose group received the fourth dose).
Time Semm IgG concentration (mg/dl)
Before 580
After 1 hour 1100
After 24 hours 840
After 7 days 820
After 14 days 750
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Figure 3.9 Serum IgG  concentration in the IV IG  and control group before and after 
the third infusion 
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Figure 3.10 Serum IgG  concentration in the IVIG group before and after the fourth 
infusion
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At 3 months o f age the mean IgG concentration in the IVIG group was 243 ± 
72 mg/dl (range: 160-260 mg/dl) in comparison to 122 + 31 mg/dl (range: 9 3 -1 6 0  
mg/dl) in the control group (p < 0.05).
These results indicate that there is no significant difference in the mean IgG 
concentration at one month between control and IVIG groups, although the mean IgG 
concentration in the IVIG group is higher than that in the control group. But at the 
age o f two and three months there was a significant difference in the mean IgG 
concentration between the IVIG and control group (Table: 3. 16).
Maternal IgG crosses the placenta predominantly in the later part o f the third 
trimester o f pregnancy, so that, at birth, serum IgG levels in premature infants are well 
below levels observed in the term infants. Levels of serum IgG at birth are directly 
proportional to gestational age and their decline during the first months o f life results 
in the preterm infants becoming severely hypogammaglobulinaemic. Table 3.20 show 
the serum IgG concentration at different gestational ages in the control group babies 
(Figure 3.11) and Table 3.21 shows serum IgG concentration at different post-natal 
ages.
3.3 Serum opsonic activity of E. coli and GBS
In this study the opsonic activity o f the premature infant's semm for E.coli and 
GBS were studied in both the IVIG and control group. Neutrophils from adult 
volunteers were used to eliminate the effect of poor neutrophil function in preterm 
infants. Due to the difference in the sources of neutrophil cells used (different 
volunteers) throughout the study period it is difficult to compare the high peak value 
o f semm opsonic activity between the babies in the two groups. Therefore the semm
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Table 3.16 Mean semm concentration o f IgG (mg/dl) at I, 2 and 3 months in the
IVIG and control groups.
Time Treatment group Control group
1 month 413 +167 273 ±63
(range: 280-670) (range: 170-370)
2 months 331 ± 183 152+49
(range: 160-750) (range: 100-230)
3 months 218 + 90 113 +32
(range: 100-670) (range: 60-160)
Table 3.17 Mean semm IgG concentration (mg/dl) at 1, 2 and 3 months at different 
birth weights in the control group.
Time/Birth weight < 1000 grams 1001— 1250 grams 1251— 1500 grams
1 month
2 months
3 months
264 ± 63 
(range: 170-340)
154 + 61 
(range: 100-230)
116 + 26 
(range: 100-160)
320 + 197 
(range: 100-230)
180 + 56 
(range: 140-220)
170 + 70 
(range: 120-300)
260 + 88 
(range: 140-340)
160+101 
(range: 120-300)
144 + 84 
(range: 160-280)
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Table 3.18 Mean serum IgG concentration (mg/dl) at 1, 2 and 3 months at different
birth weights in the IVIG group.
Time/Birthweight < 1000 grams 1001— 1250 grams 1251— 1500 grams
1 month 492 + 180 293 + 117 466 + 85
(range: 300-670) (range: 160-470) (range: 360-470)
2 months 380 + 240 237 + 43 376 + 175
(range: 160-750) (range: 200-300) (range: 200-550)
3 months 206+  121 240 + 45 210 + 20
(range: 100-360) (range: 200-290) (range: 205-216)
Table 3.19 Effect o f one dose o f IVIG on serum IgG concentration in the IVIG 
group in comparison to serum IgG concentration in control group (babies with 
matched gestational age).
Age IgG concentration mg/dl
IVIG group Control group
1 month 338.18 + 102.45 
(range: 100-470)
262.5 + 63.18 
(range: 170-340)
2 months 241.11 +71.14 
(range: 160-380)
153.33 +57.85 
(range: 100-230)
3 Months 242.66 + 71.46 
(range: 160-260)
122.33 +30.91 
(range: 93-169)
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Table 3.20 Serum IgG concentration at different gestational ages.
Gestation Age IgG Concentration (mg/dl)
2 4 -2 5  weeks 320 ± 79
25 - 26 weeks 420 + 0
26 - 27 weeks 350 + 71
27 -2 8  weeks 460+  110
28 - 29 weeks 5 4 1 ± 132
29 - -30 weeks 465 + 176
3 0 - 3 1  weeks 580+ 164
3 1 - 3 2  weeks 442 + 76
Vi,:
Table 3.21 Mean serum IgG concentration in the control group at different birth 
weights and post natal ages.
Birth weight Age in days
in grams 2 9 16 30 60 90
< 1000 460 ±146 450 ± 130 383 ± 138 264 ± 63 154 ± 61 116 ±26
1001-1250 527 ± 175 500 ± 98 400 ± 148 326 ± 193 180 ±56 170 ±70
1251-1500 432 + 96 528 + 119 434 ± 78 260 ± 88 183 ± 101 144 ± 84
Ï
101
I
I
%
600
500
400
300
200
100
0
24 25 26 27 28 29 30 31 32
Gestation Age (Weeks)
Figure 3.11 Serum IgG concentration at different gestational ages (control group)
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opsonic capacity at entry to the study was considered as 100% and the serum opsonic 
capacity at different times after the inftision o f either IVIG or 5% dextrose were 
calculated as a percentage rather than a value and compared to the 100% of the pre­
infusion level.
-v:
There was no significant difference (Tables 22-25) in the mean value of GBS 
opsonisation between the IVIG and control groups during the study period, p > 0.05 
(Figure 3.12).
There was no significant difference (Tables 26 - 29) in the E, coli opsonisation 
between the IVIG group and control group during the study period time (p > 0.05). 
Although the mean serum opsonic capacity for E. coli in the IVIG group especially 
during the second and third infusion study period was higher than that in the control 
group, the difference did not reach a significant level (Figure 3.13).
There was no significant difference (Tables 30 - 37).in the mean semm opsonic 
capacity for E. coli and GBS between the infected and non-infected babies in either 
IVIG group or the control group at any time during the study period (p> 0.05). This 
is shown in Figures 3 .1 4 -2 1 .
I
-
The comparison of the semm opsonic capacity of E.coli and GBS in the IVIG 
and control groups measured during the pre-infusion and post-infusion period at 
different times during the study period (at 1,7,14 days) reveals no significant 
difference (p > 0.05).
From the results o f our study, there was no correlation between the semm 
opsonic capacity o f E.coli and GBS, IgG concentration at different times during the 
study period and the time o f infection episodes with certain micro-organisms.
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Table 3.22 Serum opsonisation o f GBS (mean ± SD) in IVIG and control groups
during the first inftision period
Time IVIG group Control group
Before 100% 100%
24 hours 95.7 ±37% 106.2 ±30%
7days 108.2 ±51% 109.58 ± 32%
14 days 115.8 ±104% 118.72 ±63%
ni (IVIG) =17 
n2 (control) = 1 7
Table 3.23 Semm opsonisation o f GBS (mean ± SD) in IVIG and control groups 
during the second infusion period
Time IVIG group Control group
Before 73.76 ±27.7% 85.76 ±8 .6%
24 hours 93.22 ±46.8% 97.9 ±23%
7 days 88.52 ± 35% 94.1 ±29.4%
14 days 88.1 ±42.3% 113.4 ±27.5%
ni (IVIG) =5 
nz (control) = 5
Table 3.24 Semm opsonisation o f GBS (mean ± SD) in IVIG and control groups 
during the third infusion period
Time IVIG group Control group
Before 76.8 ±39.2% 93.9 ± 9%
24 hours 172.63 ±18.1% 80.15 ±2 .5%
7 days 67.84 ±24.7% 65 ± 8%
14 days 89.1 ±53% 65.75 ±91%
m (IVIG) =2
U2 (control) = 2
"i-
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Table 3.25 Semm opsonisation o f GBS in IVIG group during the fourth infusion 
period (n =1)
Time IVIG group
Before 5E6%
24 hours 37%
7 days 67 8%
14 days 48.7%
Table 3,26 Semm opsonisation o f E.coli (mean ± SD) in IVIG group and control 
group during the first infusion period.
Time IVIG group Control group
Before 100% 100%
24 hours 173.74 ± 140.8% 106.27 ±36.96%
7 days 148.88 + 107.94% 114.71 ±49.16%
14 days 187.31 ±148.1% 112.6 ±64.66%
ni (IVIG) = 17 
n2 (control) = 17
Table 3.27 Semm opsonisation o f E.coli (mean ± SD) in IVIG and control groups 
during the second infusion period.
Time IVIG group Control group
Before 134.5 ±69.07% 104.32 + 61.39%
24 hours 138.14 + 98.51% 112.96 + 55.9%
7 days 134.06+ 104.23% 107.34 + 51.96%
14 days 166+ 147.63% 94.24 + 58.91%
Ill (IVIG) = 5 
n2 (control) =5
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Table 3.28 Serum opsonisation of E.coli (mean ± SD) in IVIG and control groups
during the third infusion period.
Time IVIG group Control group
Before 202.16+ 191.96% 56.3+21.21%
24 hours 223.86 ±205% 46.85 + 18.59%
7 days 218.7+109.31% 41.8 + 30.46%
14 days 186.4 + 81.17% 61.6 + 8.62%
ni (IVIG) = 2 
n2 ( control) = 2
Table 3.29 Serum opsonisation o f E. coli in IVIG group during the fourth infusion 
period (n =1)
Time IVIG group
Before 243.8
24 hours 355.2
7 days 278
14 days 337
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Figure 3.12 Mean serum opsonic activity o f GBS in babies in the IVIG and control 
groups [ni (control) = 17 n2 (IVIG) “ 17]
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Figure 3.13 Mean serum opsonic activity o f E. coli in babies in the IVIG and control 
groups [ni (control) = 17 nz (IVIG) = 17]
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Table 3.30 Serum opsonic activity (mean ± SD) of E. coli in infected babies in the
IVIG and control groups during the first infusion period
Time IVIG group Control group
Before 100% 100%
24 hours 137+ 88.9% 108.5 +47.15%
7 days 136.32 + 55.16% 112.38 + 51.49%
14 days 136.7 + 67.14% 122.36 + 81.6%
ni(IV IG) = 5 
% (control) = 9
Table 3.31 Serum opsonic activity (mean ± SD) of E. coli in infected babies in the 
IVIG and control groups during the second infusion period
Time IVIG group Control group
Before 147.52 + 72.32% 104.32 + 61.39%
24 hours 144.65 + 112.5% 124.45 + 64.59%
7 days 148.42 + 114.49% 107.34 + 51.9%
14 dys 190.27 + 158.53% 93.24 + 58.91%
ni (IVIG ) = 4 
ÏI2  (control) = 5
Table 3.32 Serum opsonic activity (mean ± SD) o f E. coli in infected babies in the 
IVIG and control groups during the third infusion period
Time IVIG group Control group
Before 252.3 +242.1% 56.3+ 21 .2%
24 hours 283 +251.16% 48.85 + 18.5%
7 dys 218.7+109.3% 41.8 + 30.4%
14 dys 186.4 + 81.1% 61.6 + 80.6%
n i(IV IG ) = 2
Ü2  (control) = 2
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Table 3.33 Serum opsonic activity (mean ± SD) of GBS in infected babies in the
IVIG and control groups during the first infusion period
Time IVIG group Control group
Before 100% 100%
24 hours 91.36 + 27.4% 101.6 + 32.16%
7 days 100.28 + 64.91% 110.27 + 41.4%
14 days 72.72 + 27.65% 124.82 + 80.7%
ni (IVIG) = 5 
112 (control) = 9
Table 3.34 Serum opsonic activity (mean ± SD) of GBS in infected babies in the 
IVIG and control groups during the second infusion period
Time IVIG group Control group
Before 73.22 + 31.9% 85.76 + 8.64%
24 hours 94.8 + 53.96% 97.9 + 23%
7 days 90.3 +40.2% 148.1 + 148.4%
14 days 93 .75+46.63% 113.4 + 27.48%
ni (IVIG) =4 
112 (control) = 5
Table 3.35 Serum opsonic activity (mean ± SD) in infected babies in the IVIG and 
control groups during the third infusion period
Time IVIG group Control group
Before 71.2 + 53.7% 93. + 9.05%
24 hours 65.95 +49.56% 80.15 +2.87%
7 days 67.85 +24.67% 65 + 8.05%
14 days 89.1 +53.03% 65.7 + 9.2%
ni (IVIG) = 2
ÏÏ2  (control) = 2
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Table 3.36 Serum opsonic activity o f E, coli (mean ± SD) in non infected babies in 
the IVIG and control groups
Time IVIG group Control group
Before 100% 100%
24 hour 197.23 ± 166.87% 105.43 +27.19%
7 days 156,45 + 129.2% 119.66 + 48.16%
14 days 181.6 + 171.27% 101.75 +40.99%
ni (IVIG) = 12 
1Ï2 (control) = 8
Table 3.37 Semm opsonic activity o f GBS (mean ± SD) in non infected babies in the 
IVIG and control groups
Time IVIG group Control group
Before 100% 100%
24 hour 96.06 + 43.83% 113.3+31.06%
7 days 105.37 + 50.95% 110.87 + 24.13%
14 days 128.2 + 121% 111.80 + 39.93%
111 (IVIG ) = 12 
U2 (control) = 8
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Figure 3.14 Semm opsonic activity o f E. coli in infected babies in the IVIG group
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Figure 3.15 Semm opsonic activity o f GBS in infected babies in the IVIG group
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Figure 3.16 Semm opsonic activity o f E.coli o f semm from non infected babies in the 
control group
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Figure 3.17 Serum opsonic activity o f GBS o f serum from non infected babies in the 
control group
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Figure 3.18 Serum opsonic activity o f E, coli o f non infected babies in the IVIG 
group
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Figure 3.19 Serum opsinic activity o f GBS of non infected babies in the IVIG group
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Figure 3.20 Semm opsonic activity o f E. coli o f infected babies in the control group
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Figure 3,21 Serum opsonic activity o f GBS o f infected babies in the control group
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Figure 3.22 Mean semm IgG concentration in non-infected babies receiving the first 
infusion in the IVIG group 
(n= 12)
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Figure 3.23 Mean semm IgG concentration in non-infected babies receiving the 
second infusion in the IVIG group 
(n= 1)
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Figure 3.24 M ean serum IgG  concentration in infected babies in the IV IG  group
before and after the first infusion
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Figure 3.25 M ean sem m  IgG  concentration in infected babies in the IV IG  group 
before and after the second infusion 
(n = 4)
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Figure 3.26 Mean serum IgG concentration in infected babies in the IVIG group
before and after the third infusion
(n=2)
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Figure 3.27 Mean serum IgG concentration in infected babies in the IVIG group
before and after the fourth infusion
(n=l)
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Figure 3.28 Mean serum IgG concentration in infected babies in the control group
before and after the first infusion
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Figure 3.29 Mean semm IgG concentration in infected babies in the control group
before and after the second infusion
(n=5)
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Figure 3,30 Mean semm IgG concentration in infected babies in the control group
before and after the third infusion
(n= 2)
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Figure 3,31 Mean semm IgG concentration in non-infected babies in the control 
group before and after the first infusion 
(n =  8)
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2 .4 Side effects
In the treatment group there was no significant difference in HR, RR, BP at 30 
minutes pre-infusion, 30 minute intervals during the infusion and 30 minutes post­
infusion. No temperature instability (±1 °C) was noted. All o f the infants were 
clinically stable at the time o f the infusion. There were no significant changes in urine 
samples tested for blood and protein before, and 24 hours after the infusion. Serum 
glucose, electrolytes, osmolality, total bilimbin, blood urea, haemoglobin, WBC and 
platelets showed no significant difference before, during and after the IVIG inflision.
There was no significant difference in the mean haemoglobin concentration 
before the infusion and after 24 hours. Seven babies in the IVIG group had a decrease 
in the mean haemoglobin (14.17 ± 2.42 g/dl, range: 12.4 - 18.7) and haematocrit 
concentration 24 hours after the infusion but this decrease was not significantly 
different from the mean pre-inftision level (16.36 ± 2.04 g/dl, ranges: 14.1 - 20.5).
This decrease in the haemoglobin was also noted in the control group. Six 
babies showed a decrease in the mean haemoglobin from 16.7 ± 2.86 g/dl (range: 13.5 
- 20.8) to 14.0 ± 2.4 g/dl (range: 11.6 - 17.5) post-infusion, p > 0.05. These results 
also shows no significant difference. This reduction in haemoglobin level may be due 
to blood sampling, hemodilution, low semm eiythropoietin levels and the course of 
their illness.
In addition there was no significant difference in the duration o f phototherapy 
between the two groups as there was no significant difference in the semm bilimbin 
levels.
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9.2 mmol/dl at 33 days old and returned to normal level within 5 days. At that time 
she had infection episodes and suspected necrotising enterocolitis.
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Seven (7) out of seventeen (17) babies in the IVIG group (41.7%) developed 
IVH/PVH in comparison to ten (10) out o f seventeen (17) babies in the control group 
(58.8%). This was not statistically significant. = 0.750, 0.10 < p < 0.50.
There was no evidence o f renal impairment in infants who received IVIG. There 
.was no significant difference in the mean blood urea and serum creatinine
-concentration before the infusion and 24 hours, 7 days and 14 days post-infusion in 
the IVIG and control groups. There was an increase in blood urea in a number of 
babies in both groups. Four babies in the control group and two babies in IVIG group 
showed an increase in blood urea concentration during the 14 days post-infijsion 
period (but no significant difference in blood urea between the pre-infusion level and 
l,7and 14 days post-infusion, p > 0.05). During the period o f increased blood urea,
the babies were unwell, three babies in the control group had bronchopulmonary 
dysplasia and were being treated with dexamethasone which could have accounted for
the rise in blood urea. An increase in blood urea may be due to the course o f the 
illness rather than to any effect o f IVIG given.
One baby in the treatment group developed neplirotic syndrome at the age of 
120 days. This baby had received four doses o f IVIG. Blood urea was increased to
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Chapter 4 
DISCUSSION
4.1 Effect of IVIG in the prophylaxis of late onset sepsis
There are a variety o f host defence abnormalities in neonates that help to explain 
the susceptibility o f neonates to ovei*whelming bacterial infection. Many methods of 
treatment have been tried to correct the host defence abnormality in preterm babies. 
These include granulocyte transfusion, fibronectin and immunoglobulin transfusion. 
But the only method o f treatment that gaves some satisfactory results in some studies 
was immunoglobulin inflision.
In different trials immunoglobulin was given in different protocols, preparations 
and doses, as well as to different study populations to prevent or to reduce the 
incidence o f infection in neonates. These studies have focused on the VLBW infant in 
an attempt to correct the postnatal physiological and profound hypogamma- 
globulinaemia.
M ost o f the studies monitored nosocomial bacterial infection. The reported 
studies have employed different types o f immunoglobulin preparations, different dose 
regimens, and a varied range of duration o f IVIG therapy. Some studies provided 
IVIG during part but not during all o f the potential at risk period for infection.
In some o f these studies, the infection rate was reduced during the IVIG 
treatment period and increased during the period when the infants did not receive 
IVIG therapy.
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Since the study in 1963 by Amer et who noted a reduction in the
incidence o f death and non-lethal infection o f premature neonates by administration of 
intramuscular injection o f IgG at a dose o f 3 ml/Kg every month, a number of 
subsequent studies were carried out using IVIG which is less painful to administer. 
These studies explored the relationship between the administration o f IVIG and the 
prevention or treatment o f neonatal infection. As noted in the review o f literature, 
many trials did not convincingly answer the question of the efficacy o f IVIG in the 
prophylaxis or treatment o f bacterial infection.
Over all, some o f these recent studies have demonstrated a beneficial effect o f 
IVIG in reducing the incidence o f nosocomial infection in VLBW infants, while others 
have not shown any statistical difference in the rate o f infection.
These differences might be related to the dosing regimens, constitution of the 
IVIG preparation, sample size, definition o f infection or the incidence o f infection in 
the study population.
The aim o f this study was to evaluate and compare the efficacy o f IVIG on the 
prevention o f sepsis in vulnerable VLBW infants who suffered from respiratory 
difficulty early in life, needed intensive life support and various procedures including 
intubation, umbilical venous and arterial catheterisation, insertion o f long lines and 
drainage o f  pneumothoraces. All of these procedures are traumatic and carry with 
them an increased risk o f infection.
Most studies reviewed administered IVIG to babies born prematurely and given 
according to their birth weight but did not specify whether this was limited to those 
needing intensive life support. Therefore the incidence o f infection in their studies may
123
iîbe low in the control and treatment groups in comparison to the incidence o f sepsis in 
this study.
level.
ventilation, umbilical catheters, pleural drainage, total parenteral nutrition) to potential 
infectious agents, and a very under-developed immune mechanism, so that IVIG 
therapy alone may not alter the incidence o f infection.
Because o f the small number o f babies included in our study, our study was not
In our study IVIG was given to VLBW infants needing intensive care and aimed
at preventing late onset infection. Data obtained from our results show no significant
reduction in the incidence o f proven sepsis in the IVIG treated group. Despite the
.observation o f decreased incidence o f proven sepsis in IVIG treated group (29.9%) in
.comparison to the control group (52.9%), this does not reach a statistically significant
The incidence o f infection was more obvious in babies with birth weight
< 1000 grams (IVIG and control group) probably due to their prolong stay in 
.intensive care and prolonged exposure to invasive techniques (e.g., mechanical
3
I
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4able to show any statistically significant effect of IVIG therapy in the prevention of
infection in VLBW infants. This is consistent with the results obtained from many 
other studiesf^'^^’^ ^^ ’^ ^^ ’^ ^^ b
The question still to be answered is whether IVIG has any role to play in the 
prevention o f late onset sepsis in VLBW infants. From the results o f our study, we are 
not able to answer this question. One point to be considered is the high incidence o f 
proven sepsis in the control group in comparison to the IVIG treated group where 
both had similar clinical parameters, and both received the same treatment and 
intensive care management.
I
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In this study the infection episodes occurred in the group o f babies receiving 
IVIG when IgG levels were below 680 mg/dl. In the group which received 5% 
dextrose, infection occurred when IgG concentration was below 640 mg/dl. We did 
not measure the IgG level at the time o f infection. Other studies demonstrated an 
increased incidence o f infection among infants with serum IgG  levels below 400 
mg/dll'“ >.
Therefore the best result o f IVIG administration may be obtained by maintaining 
the serum IgG concentration above the target level of 700 mg/dl (the lower limit of 
the normal IgG concentration in full term infants). This level can be achieved by 
frequent measurement and administration o f IVIG to maintain the serum IgG level.
The reduction in the number o f proven septic episodes in our study (within 14 
days post-infusion) in the IVIG group was approximately 40% in comparison to the 
control group, even though this reduction did not reach the significant level. This is 
consistent with the result obtained by Baker et al.^ '^^ ^^  who noticed a reduction in the 
incidence o f proven sepsis o f approximately 30% when IVIG was given during the 
first, and second weeks and at fortnightly intervals thereafter.
The infants in our study did not develop infections with organisms widely 
recognised as pathogens in neonates such as gram negative rods or group B 
streptococci. Rather, the infecting microflora represented organisms commonly 
encountered in nosocomial infection in many intensive care units. This included a high 
rate o f Staphylococcus infection.
88.5% o f infective episodes in both the IVIG and control groups were due to 
Staphylococcus epidermidis, 5.7% were due to Candida albicans, 2.9% were due to 
Enterobacter species and another 2.9% were due to Enterococcus faecalis. These
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were nearly the same micro-organisms noted in other studies where most o f the Iepisodes o f infection were caused by Staphylococcus epidermidis and S. 
aureus^^^^’^ '^^ ’^ ^^ .^ Weisman et alj^^^  ^ noted that two thirds o f the infected babies in 
their study were infected with gram positive organisms, most commonly S. 
epidermidis. S
.
It is the increased survival o f these high risk infants which results in long stays in 
intensive care units resulting in increased exposure to microflora that leads to y
nosocomial infection with those micro-organisms. The development o f  infection with 
these organisms is usually associated with the use o f indwelling catheters, respirators 
and other invasive procedures rather than to low antibody levels.
The most common cause o f early onset neonatal sepsis in most neonatal units 
continues to be group B streptococci and E. coli. Both o f these pathogens are 
encapsulated and the antibody plays an important role in effective phagocytosis and 
killing o f these bacteria, although recent data suggest that there may be a role for the I
antibody in the killing o f other pathogens such as S. epidermidis^^^^^. The role o f the
#antibody against other neonatal pathogens such as Candida albicans and Enterococci
T:.
remains to be determined. Therefore the role o f IVIG therapy is less clear where these 
pathogens predominate as occurs in late onset sepsis.
Î
It is unlikely, therefore that any IVIG focused on the prevention o f infection ;|Icaused by these organisms will ever show truly beneficial prophylactic effects.
4;,
■f.
I88.2% o f mothers in the control group as opposed to 52.9% o f mothers in the 
IVIG group received ante-natal steroids. However none o f the babies in the IVIG 
group and control group had infection during the first 5 days of life making it unlikely 
that any o f those infections was due to maternal ante-natal steroid therapy. A previous
s t u d y s h o w s  that prenatal and/or postnatal steroid treatment does not affect PMNs 
chemotactic maturation in preterm neonates.
The results o f our study did not show any significant difference in suspected 
septic episodes between the two groups during the 14 day post infusion period. But 
the incidence o f suspected sepsis after 14 days post-infusion was significantly 
increased in the IVIG group. This difference was mainly noted in babies with birth 
weight o f 1001-1250 grams. This difference may be due to the development o f a chest 
infection in three babies and high colonisation with different types o f micro-organisms 
such as S. epidermidis, S. aureus, Enterobacter species, Enterococcus faecalis and 
Pseudomonas pyocyanea.
We noted an increase o f suspected septic episodes in both groups. Some of 
these episodes may have been true infection episodes, as it is known the microbiologie 
cultivation techniques do not detect all episodes of infection. The frequent use of 
antibiotics in this population may affect the rate of recoveiy o f pathogenic micro­
organisms. Some o f these infection episodes may have been due to viral infection 
which can not be detected by ordinaiy culture methods. For this reason, we examined 
the effect o f IVIG on other parameters such as duration o f antibiotic therapy, the 
duration o f intensive life support and hospitalisation. We found that the administration 
o f IVIG did not alter the duration o f any o f these parameters.
A better strategy in the future may be the use o f hyperimmune intravenous 
immunoglobulin or human monoclonal antibody preparations aimed at treating rather 
than preventing a particular neonatal infection.
Some studies^^*'^’^ '^ ^^  suggest that low concentrations o f complement may 
contribute to the development and severity o f bacterial sepsis in neonates and may
1
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restrict the efficacy o f proposed adjunctive therapies, such as the administration of 
IVIG.
The failure o f many studies to show any beneficial effects of IVIG in reducing 
the incidence o f infection may be due to many factors. The antibodies administered 
may not have been effective against the infecting pathogens, non immunoglobulin 
mediated host defence impairment (e.g., complement, neutrophil, fibronectin) 
interfering with the impact o f standard IVIG therapy, reduced availability o f antibody 
at the infection site, failure to achieve a target level o f serum IgG or lack o f sufficient 
sample size to detect such deficiencies or other unidentified variables.
The results o f our study did not show any significant effect o f IVIG in the 
incidence o f suspected necrotising enterocolitis. The role o f immunoglobulin therapy 
for enteric diseases and necrotising enterocolitis is unclear. Several studies^^^^’^ ^^  ^ have 
addressed the role of IVIG in preventing nosocomial infection and necrotising 
enterocolitis in LBW infants and full-term infants, but only one^ *^"^  ^ o f them addressed 
gastrointestinal illness in full term and premature infants. It shows that administration 
of IVIG had no substantial effect. More specific therapy with oral immunoglobulin 
preparation has been suggested to prevent NEC. Eibl and co-workers^^'^^^ performed a 
randomised clinical trial using an oral immunoglobulin preparation (37% IgA and 26% 
IgG) in the prevention o f NEC in infants weighing between 800 and 2000 grams at 
birth. No cases o f NEC occurred among 88 infants receiving the oral IgA-IgG 
compared to 6 cases of NEC among 91 control infants. In our study we did not see 
any effect o f breast milk in the prevention o f systemic infection or sign o f suspected 
necrotising enterocolitis
In our study only 34.2% of proven septic episodes were accompanied by a 
raised C- reactive protein level. Two episodes were due to Candida septicaemia and
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phase response. It has been shown that E. coli gives the most reliable increase in C- 
reactive protein^ ^*^ ^ ,^ whereas in Sann's study^^^^  ^ early onset group B streptococcal 
infection was less reliable.
In Sann's study, the semm C- reactive protein concentration was normal in 27% 
of patients with septicaemia. This was higher than that found by Sabel et a^^^l
I
10 episodes were due to S. epidermides. This could be due to the fact that some 
infants seem to be incapable o f mounting an appropriate acute-phase response^^ '^ '^^^^l 
Also it could be due to different organisms stimulating different patterns o f acute-
tir
C“ reactive protein is an acute phase protein synthesised by the liver within 6-8 
hours o f an inflammatory stimulus. It is produced most rapidly in response to bacterial 
infection. Although this response is non-specific, it is thought to give indirect evidence 
o f infection.
. . . .Therefore in some neonatal units C- reactive protein is used in conjunction with 
good clinical assessment for the early diagnosis o f infection, while the results of blood 
cultures are awaited. Semm C- reactive protein reflects the immediate effect o f the 
treatment, therefore serial C- reactive protein measurements have been used for 
monitoring the efficacy o f antibiotic treatment and to detect any recurrence o f 
infection.
4.2 Effect of IVIG on serum IgG concentration
In babies < 1000 grams birth weight the dose of 700 mg/kg o f IVIG raises the 
mean semm IgG concentration one hour after the infusion to 280% of the pre­
infusion level. The dose of 500 mg/kg o f IgG increased the mean serum IgG :
12<)
concentration by 215% in babies weighing 1001 to 1250 grams and by 185% in babies 
weighing 1251 to  1500 grams.
The increase o f IgG concentration was affected by the post-natal age. The dose 
o f 700 mg/kg given to babies with birth weight < 1000 grams two days after birth 
increased the mean IgG concentration to 280% from the pre-inftision level,while the 
same dose given after two weeks increased the mean serum concentration to 226% of 
the pre-inftision level. At one month o f age when the third dose was given the level 
peaked at 205% o f the pre infusion level. The fourth dose was given at 6 weeks of 
age and increased the mean semm IgG concentration to 189% of the pre-infusion 
level.
The pharmacology o f IVIG fits into a two phase disappearance curve. The first 
phase is short, beginning immediately after the infusion is administered. It lasts 1 to 4 
days and may represent the redistribution o f IgG between intravascular and 
extravascular compartments and clearance o f denatured or aggregated IgG. In our 
study the semm IgG concentration declined by 19% to 28% from the peak post­
infusion level 24 hours after an infusion. This was in keeping with obsei*vations made 
in other studies^^^^’^ *^"^ where the IgG declined by 20% to 30% 24 hours post­
infusion. We measured IgG on day 7 post-infusion and the level declined by 26% to 
45% o f peak post-infusion level.
This obseiwation was noted by Noya and colleagues^^^^’^ ^^  ^who reported a 40% 
decline o f semm IgG level within one day o f an infusion among very low birth weight 
infants. The semm IgG level declined to 50% of post-infusion level within 3 to 5 days.
The second component is the half life and represents the catabolism of IgG 
which is linear and may be a better determinant of the required dose and dosing
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interval to  maintain the semm IgG at a therapeutic level. The half life o f semm IgG in 
neonates is quite variable and difficult to predict^ The half life is dependent on 
gestation age, post-natal age, the presence or absence of infection, the level o f total 
serum IgG, size o f the extravascular space, functional activity o f the IVIG and 
catabolic rate.
In neonates the short half life o f IgG o f about 11 to 14 days (4 to 7 days for a 
specific antibody) may result in part from an increased catabolic rate o f administered 
gammaglobulin, consumption of antibodies by frequent neonatal infection or loss o f 
protein in infants with renal or intestinal disease.
In this study the semm level o f IgG measured 14 days post-infusion declined by 
32% to 51% of the peak post-infusion level. This decline (after the first infusion) 
varied slightly between neonates of different birth weight. For instance it declined to 
53% o f the peak post-infusion level in infants with birth weight < 1000 grams and to 
60% in infants with birth weight 1251 to 1500 grams.
A significant variability was observed among these individual neonates with 
respect to the half life o f the infused IVIG which depended on several factors 
(discussed before) and on the peak serum IgG concentration.
According to recent datal* "^ ’^^ *^"! it is important to achieve and maintain the 
target level of semm IgG o f 700 mg/dl (this level was chosen as the lower limit of the 
normal range o f semm IgG in the cord blood among term infants) during the first 
month o f life which is the high risk period for infection secondary to the wide use of 
invasive procedures.
131
60% o f infusions. Even among infants weighing more than 1000 grams, it was
I
Among neonates in our study with birth weight <1000 grams a dose o f 700
mg/kg every two weeks did not sustain a target level o f 700 mg/dl for 7 days in 69%
of infusions and for 14 days in 77% o f infusions. Also a dose o f 500 mg/kg eveiy two 
.weeks given to infants with birth weight o f 1001 to 1500 grams failed to sustain the 
target level for 7 days in 58% of infusions and for 14 days in 91% o f infusions. Similar 
results were observed by Kyllonen et al.^ ^^ "^  ^in which a target level o f 700 mg/dl was 
achieved in 90% of infusions performed in neonates weighing >1000 grams with a 
dose o f 700 mg/kg. Tsakalidou et also attained similar concentrations of at least 
10 days duration in 81% of the infusions o f 500 mg/kg.
Noya and colleagues^^^^^ demonstrated a rapid decline o f serum IgG 
concentration after one dose o f IVIG to VLBW infants. The semm IgG concentration 
declined below 700 mg/dl 7 days after a dose o f 500 mg/kg among 2 to 3 day old 
1100 gram infants, but a dose o f 1000 mg/kg was able to sustain this target level.
The small, less mature infants had an increased IgG half life with increased post­
natal age which suggests the need for a shortened dosing interval in the first few 
weeks o f life. The change in IgG elimination rate with time appears to be related to 
maturity.
Among neonates with birth weight o f less than 1000 grams a dose as high as 
900 mg/kg eveiy two weeks did not sustain a target level o f 700 mg/dl for 14 days in
K
difficult to sustain semm levels for two weeks with a dose o f 500 mg to 900 mg/kg of 
IVIG'"'*',
M
These findings suggest that although administration o f IVIG at conventional 
doses may result in a satisfactory increase o f the total serum IgG levels in neonates
-4
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with birth weight > 1000 grams, it may not result in an analogous increase o f all IgG 
subclass levels.
Specific antibodies belong to certain IgG subclasses. Antibodies against 
bacterial polysaccharide antigens are contained mainly in IgG2 and IgG4^^^^’^ ''^l One 
could hypothesise that it may be desirable to achieve and maintain a target serum level 
o f not only total IgG but also IgG subclasses.
Frequent monitoring o f serum IgG levels will be necessaiy if the target level of 
IgG is to be maintained because o f the wide range o f IVIG kinetics in VLBW infants.
For the optimal use o f IVIG, the dose given to preterm babies may need to be 
individualised on the basis o f the serum IgG level drawn 48 to 72 hours after the 
initial infusion when the inflised IgG has equilibrated into the extravascular 
compartment. This level needs to be checked again 7 days later if the target level is to 
be maintained.
Results o f our study show that infection episodes developed when serum IgG 
was as high as 680 mg/dl, but another study^^^^  ^ demonstrated infection episodes when 
IgG was at less than 400 mg/dl.
The level o f IgG in premature infants is determined by the amount o f maternal 
IgG transferred across the placenta, by the catabolism o f maternal IgG and by the rate 
o f synthesis o f the infant's own immunoglobulin. This rate o f synthesis is minimal in 
premature infants. In the blood o f the preterm infants, the IgG concentration is low at 
birth and declines rapidly after. Therefore the group o f babies receiving 5% dextrose 
represent the normal level o f serum IgG in preterm babies o f different birth weights 
and post-natal ages. The mean IgG concentration at birth in babies with birth weight <
I
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1500 grams was 467 ± 137 mg/dl (ranges: 240-710 mg/dl) with wide variability 
among neonates. This is in keeping with Backers study^^^^l Another study showed a 
reduced IgG concentration o f under 200 mg/dl within a few weeks after birth.
The mean concentration of IgG in the control group at different postnatal ages 
was shown in Table 3.17. This is equivalent to the normal IgG concentration in 
premature infants at different gestational age (Tablet. 1).
These findings are nearly the same as the IgG level in babies born prematurely at 
29 to 33 weeks gestation in the study o f Ballow et al.^ ^™^ , who found the mean IgG 
concentration was 368 mg/dl at birth, declined to 104 mg/dl at 3 months of age, and 
then slowly increased. Ballow and coworkers also found the mean concentration of 
IgG was increased only to 280 mg/dl at 10 months of age.
In another study^^^^l infants with birth weight of <1000 grams had serum IgG 
levels at birth o f 489 ± 8 1  mg/dl and that they declined to 130 ± 34 mg/dl by 10 
weeks o f age, whereas those of >1000 grams had mean cord blood IgG level o f 736 ± 
47 mg/dl wliich declined to 418 ± 34 mg/dl by the first month o f life. Another 
s t u d y d e m o n s t r a t e d  markedly low semm IgG levels among small infants born 
between 25 to 28 weeks, with a semm IgG level as low as 60 mg/dl at 3 months of 
age. These lower semm levels may be associated with a high risk o f infection.
In our study, even one dose o f IVIG could maintain the serum IgG 
concentration at a higher level than in those who did not receive any IVIG (Table 
3.20). One dose o f IVIG kept the IgG concentration at age of one month at 130%
' i'
higher than in the control group, 157% higher at 2 months o f age and at 200% higher 
at 3 months. These higher levels were significant at ages 2 and 3 months but not 
significant at the age o f one month.
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In our study 29% of infants had a serum IgG level less than 200 mg/dl at the 
age o f one month, 50% had a serum level o f less than 200 mg/dl at two months and 
90% had a serum level of less than 200 mg/dl at the end o f the third month.
These results indicate an increased susceptibility o f preterm babies to infection 
during the first 3 months o f life especially during the first month when most invasive 
procedures are carried out.
4.3 Serum opsonic activity of E. coli and GBS
As we noted from the results o f our study there was no significant effect of 
IVIG on serum opsonic activity for GBS and E. coli. This may be due to several 
factors including deficiency o f complement as the serum was heated for 30 minutes at 
56 °C to remove the effect o f the complement, the IVIG used had decreased quantity 
o f intact IgG, or the IVIG had a significant lot-to-lot variability in the concentration 
o f fiinctional type specific antibody.
Also there was no correlation between the time of infection episodes, serum 
opsonic capacity for E. coli and GBS, and the IgG concentration. There were no 
infection episodes when IgG concentration was more than 680 mg/dl.
The high peak values o f E. coli opsonisation in some babies in the IVIG group 
were higher than those in the control group, and even the mean o f the high peak value 
o f E. coli opsonisation was higher than the mean in the control group but this did not 
reach a statistically significant level. This observation may be due to a high 
concentration o f specific anti-E. coli antibody in the IVIG used.
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complement levels leading to deficient opsonisation.
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However the serum opsonic capacity for GBS was not different in the IVIG 
group from that in the control group. One explanation might be due to a low 
concentration o f specific anti-GBS antibody in the IVIG used, or to deficient
Opsonisation is the process by which bacteria are prepared for ingestion and 
intracellular killing by phagocytes such as neutrophils. Usually neutrophils do not 
recognise or ingest pathogenic bacteria unless the organisms are opsonised by the 
deposition of antibodies and/or complement proteins onto the bacterial surface. Many
1
::4encapsulated bacteria such as type III group B streptococci and E. coli that express
the K antigen resist activation o f complement by the alternative pathway^ 
Moreover in the absence o f a complement source, these organisms are not efficiently 
opsonised by the deposition o f an antibody aloiW^^^'^^^l
The organisms are ingested and killed efficiently by neutrophils after the surface 
deposition o f both antibodies and complement proteins, especially degradation
products o f C3. Antibodies such as those that comprise IVIG must work in concert 
with the complement systems and neutrophils to achieve efficient opsonisation and
bacterial killing.
In the serum of the preterm and ill full term baby, opsonisation was 
i n e f f i c i e n t ^ A l t h o u g h  antibody deficiency may have accounted for this 
observation, it is possible that diminished complement concentration and activity may 
restrict the opsonic capacity o f neonatal serum. For example, the concentration of 
various complement proteins have been noted to be diminished in the serum of septic 
neonates compared with those of healthy neonates. Death in septic neonates has been 
associated with decreased complement activity in the sera o f the non-survivors^^^^^.
.1I4:
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The capacity o f septic neonates serum to deposit C3 onto pathogenic bacteria was 
diminished and was not consistently enhanced by the IVIG inlusion^^^^l
Marked variations were obseiwed in the CL response with different bacteria and 
PMN from different normal donors. The variation among organisms may reflect 
activation o f different metabolic pathways by various bacteria and the generation of 
different types and/or amounts o f oxidative species. These are most likely to 
contribute to variations in CL among bacteria. Additionally, the extent o f opsonisation 
were represented by both quantitative and qualitative differences in the type and/or 
the amount of semm opsonins like complement components or immunoglobulins 
coating the bacteria. The direct relationship between the amount o f semm per 
bacterium and the amount o f CL certainly suggests a cretical role for semm opsonins 
on the kinetics of CL.
The large range in the CL response among PMNs from different donors also 
suggests basic differences in the PMNs metabolic activity o f normal people. These 
cellular differences could reflect variations in recognition, ingestion, enzymes, or 
oxidative species and enzymes released during phagocytosis.
Luminol-dependent CL is useful in determining semm opsonic activity because 
it is dependent on heat labile factors, such as complement, and correlates with the 
amount o f semm per organism used for pre-opsonisation.
88% of infection episodes in this study were due to S. epidermidis. Therefore 
either there was a low concentration o f anti-S. epidermidis antibody in the IVIG 
preparation used in this study or the anti-S. epidermidis antibody concentration was 
adequate but the antibody was not effective against this micro-organism. Recent data 
suggest there may be a role for the antibody in the killing o f pathogens such as S.
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ep i de r mi d i s ^ ^ and  that there is an important role o f the antibody in the infective 
phagocytosis and killing o f E. coli and GBS. However the role o f the antibody against 
other neonatal pathogens such as Candida albicans and enterococci is not known.
In this study 66.6% o f S. epidermidis infection episodes were associated with 
the presence o f a central intravenous long line. The most important factors affecting 
the incidence o f infection are prematurity, as 88% of infection episodes occurred in 
babies with birth weight < 1000 grams and the presence o f a central intravenous long 
line. The group o f babies with birth weight < 1000 grams needed a prolonged period 
o f intensive life support, more intensive care procedures such as intubation, UAC, 
UVC, central intravenous lines and drainage of pneumothoraces than those with birth 
weight > 1000 gram.
4.4 Side effects
We found that the infusion o f 500 mg/kg and 700 mg/kg o f IVIG to preterm 
infants with birth weight o f < 1000 grams and 1001 to 1500 grams respectively was 
safe. There were no instances o f hypersensitivity, inflammatory or toxic reactions as 
indicated by changes in the physiological or laboratory parameters.
These results support the observation from previous reports that neonates 
generally tolerate the infusion o f IVIG quite y/QUl^^^433,i4ij48i ^hese are consistent 
with previous reports that adverse reaction to any transfused blood products in 
neonates is rare, in the order o f 0. l%^^^^b
Our sample size was small and we would have obsei*ved only complications 
occurring with a high frequency. The incidence of suspected complications of 
administering intravenous immunoglobulin to neonates has been < 0.05%^^^^ .^
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In this study the incidence o f IVH/PVH was more in babies receiving 5% 
dextrose than those receiving IVIG, but in both groups the incidence was high, which 
may have been due to prematurity and severity o f respiratoiy distress syndrome. The 
babies included in the study were all ventilated and required extensive life support. 
This was contrary to the results o f other studies^ where there is an increase in the 
incidence o f IVH/PVH among infants receiving IVIG compared to those who did not 
receive any treatment. This finding may be related to the osmolality and the volume of 
IVIG infused or to the relatively better over all condition o f the non assigned group. 
Some previous data indicate an association between IVH/PVH and hypertonic 
inlusions when these are inflised rapidly’
In this study no significant increase o f blood urea levels was noted in babies 24 
hours post inflision o f IVIG. Two babies showed an increase in blood urea level 
during the 14 day period post-infusion but this may have been due to the course of 
their illness rather than due to IVIG,
One baby who received 4 doses of IVIG developed nephrotic syndrome at the 
age o f 120 days, the last inflision have being given at the age o f 46 days. The clinical 
picture at the time o f presentation suggested renal vein thrombosis as a cause. The 
baby needed repeated doses o f albumin and immunoglobulin. She also developed 
septicaemia with gram negative organisms at that time. The baby improved after a 
period o f one month.
There have been no reports of the development o f renal toxicity in neonates 
receiving IVIG. One study^ ^*" ’^ showed a transient increase in blood urea immediately 
after the infusion which persisted for about 6 hours after the infusion. This may be 
related to the catabolism o f the administered protein and perhaps not to impaired renal 
function.
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In adults IVIG is generally well tolerated but there have been a number of 
reports^^^ '^^^^  ^ both o f acute deterioration in renal function and pulmonaiy toxicity 
following IVIG infusion.
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The cause o f renal toxicity is not clear but it may be that high doses o f IVIG 
result in an increased plasma and blood viscosity^^^^^ which may affect capillaiy blood 
flow^^^^l The increase in plasma viscosity may be due to the large amounts o f sugar 
used as a stabiliser. This may explain why the renal toxicity is generally o f limited 
duration and is self limiting. I
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Chapter 5 
Conclusion
The ultimate goal in the management o f neonatal infection is to tiy prevent its 
occurrence. The most direct way to reduce the incidence o f this frequently devastating 
disease is to  prevent premature birth.
Development o f effective therapeutic intervention to prevent neonatal infection 
was tried before through studying the immune system and several preventative 
approaches have been used.
However, some o f these treatments have been focused on the use o f IVIG in 
premature babies with birth weight < 1500 grams or less than 32 weeks o f gestation.
From this study, we are not able to answer the question whether IVIG is useful 
in preventing infection in preterm babies. This may be due to the small number of 
preterm babies included. Although there is a high incidence o f proven infection in the 
control group as opposed to the treatment group in babies < 1000 grams birth weight, 
this did not reach statistical significance.
The administration o f IVIG may not be effective in this and other big 
multicentre studies due to several factors.
1. The administered IVIG may have inadequate titers or lack o f flmctional 
antibodies against the most prevalent pathogens in low birth weight infants e.g., 
Staphylococcus epidermidis which was the most infective agent in this study.
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2. Impairment o f other immune system components such as neutrophils, 
complement and fibronectin may limit the effect of the IVIG used.
3. Total serum IgG concentration and IgG subclass may not have been 
maintained at effective levels.
Further studies in neonates are necessaiy to determine the efficacy of IVIG in 
different clinical settings, the most effective dosing schedule, and the optimal level of 
organism-specific antibody. Standardisation or establishment o f minimum levels of 
organism-specific activity per individual batch, though difficult, may be necessary to 
ensure the inftision o f sufficient organism-specific antibody. Alternatively, specific 
hyperimmune or monoclonal antibody preparations may be required to provide 
reliable sources of effective treatment to the neonates with bacterial sepsis.
Antibody level against pathogens such as group B streptococcus, E. coli and S. 
epidermidis may vaiy from batch to batch o f the same IVIG or between the different 
IVIG preparations available on the market. It would be useful in further studies to 
know the most likely organisms causing infection in the study population so that IVIG 
containing a specific antibody is used. This may be the reason why several multicentre 
trials using pooled IVIG have failed to show any statistical improvement in outcome 
when IVIG is given prophylactically. Further studies should use specific IVIG and 
should compare its use prophylactically and as therapy.
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